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Summary
Antibiotic resistance is a growing problem around the world, and poses difficulties in
treating bacterial infections in a hospital setting. Routine operations are becoming
riskier as the threat of hard to treat opportunistic infection rises. Pseudomonas
aeruginosa has worryingly acquired carbapenem resistance, and such strains have
been granted "critical" priority for new research by the World Health Organization
(WHO), as its natural antibiotic resistance and newly observed carbapenem resistance
means that there could soon be no effective treatments remaining. It is a ubiquitious
Gram-negative bacterium now frequently found in hospitals. P. aeruginosa accounts
for an estimated 10-15% of hospital-acquired infections globally and is particularly
prevalent in clinical isolates from ventilator-associated pneumonia (VAP) and cystic
fibrosis patients.
In this work, heavy focus was placed on the P. aeruginosa type III pantothenate kinase,
a 27 kDa protein encoded for by the coaX gene which is involved in the first step
of coenzyme A biosynthesis. Unlike many bacterial species, P. aeruginosa possesses
only a single pantothenate kinase gene. The loss of PanK activity has been shown
to prevent growth and reproduction in multiple bacterial species. Inhibitors of other
PanK proteins have not been shown to inhibit growth in P. aeruginosa, likely owing to
its considerable structural divergence from other characterized PanK isoforms. Despite
this, a genome-wide ligandability screen using the previously published data of a
selenium methionine containing PaPanK identified PaPanK as a potentially druggable
target. This coupled with PaPanK’s necessity for P. aeruginosa growth makes it an
attractive target for antibiotic development.
In order to eventually develop antibiotics against carbapenem resistant P. aeruginosa
(CRPA), we have implemented a medium throughput fragment screening methodology,
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as well as methods for the purification and crystallization of PaPanK. Fragment
screening using Bio-layer interferometry (BLI) was conducted in order to probe the
active site of PaPanK and resulted in identification of a number of compounds with
micromolar dissociation constants (KD). Protein crystals, containing the PaPanK
apoenzyme and complexes with a variety of ligands, were diffracted at X-ray beamline
facilities. From these, the first crystal structures of PaPanK and PaPanK-Pantothenate
with the wild type methionine rather than selenium methionine were determined.
Additionally, diffraction data was obtained which indicated electron density for ATP
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1.1 The need for new antibiotics
While a wide array of antibiotics exist, the rate at which new classes of antibiotics are
discovered has dropped dramatically. The vast majority of antibiotic classes currently
in use were discovered prior to 1970 and many potential new classes are of limited effect
against most Gram-negative bacteria, which means that the situation remains dire
[1]. One such Gram-negative species is Pseudomonas aeruginosa (P. aeruginosa), the
carbapenem-resistant strains of which have been deemed "critical" priority for research
by the World Health Organization (WHO) and are the targets of this work [2].
1.2 P. aeruginosa infection
P. aeruginosa is an aerobic, rod-shaped Gram-negative bacterium from the γ-proteobacteria
class, and is of growing clinical significance due to its ability to develop resistance
to most known antibiotics [3]. Capable of growing rapidly at temperatures ranging
from 25-42C, it is ubiquitous in nature and is capable of causing disease in both plants
and animals. Associated with high mortality rates, it has become an increasingly
common cause of nosocomial infections of the lungs, bloodstream, urinary-tract, and
burn/surgical sites [4][5]. It has been identified as one of the primary opportunistic
infections in those with cystic fibrosis, and is associated with increased morbidity
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and mortality amongst patients with chronic obstructive pulmonary disease (COPD)
and bronchiectasis [6]. Though rarely causing pneumonia outside of hospitals, P.
aeruginosa is a common cause of pneumonia within hospitals and is the leading cause
of ventilator-associated pneumonia (VAP) [7].
P. aeruginosa possesses a number of virulence factors which contribute to its ability
to infect and harm its host. A number of studies have examined the mechanisms
by which P. aeruginosa initially attaches to surfaces and thereafter forms biofilms
[8][9][10]. Following attachment, loss of the mechanosensory protein PilY1 modulates
the activation of virulence and could be contributory to chronic infections.[11]. P.
aeruginosa expresses a number of proteins which can be directly injected into adjacent
eukarotic cells through the type III secretion system including exotoxin A (ExoA),
ExoS, ExoT, ExoU, and ExoY [12]. The most potent toxin in P. aeruginosa is the
protein Pseudomonas exotoxin A [PE], a member of the mono-ADP-ribosyltransferase
family which inhibits eukaryotic protein synthesis and leads to cell-death [13].
1.3 Antibiotic-resistance mechanisms of P. aerug-
inosa
P. aeruginosa shares an inducible ampC gene mostly found in the Enterobacteriaceae
bacterial family, encoding for a periplasmic β-lactamase protein capable of binding and
hydrolyzing many cephalosporins and most penicillins, amongst other antibiotics to
limited extents [14]. The highly-effective carbapenem class of antibiotics first emerged in
the 1970s, belonging to the Beta-lactams but posessing greater inhibition against many
resistant strains of bacteria including P. aeruginosa. Birnbaum et. al (1985) attributes
the ability of carbapenems to resist β-lactamase activity moreso than other β-lactams to
its structure, which contains a trans oriented hydroxyethyl side chain, rather than the
typical cis acylamino side chain [15]. This class of antibiotics has expanded to include
impinem, panipenem, meropenem, biapenem, ertapenem, doripenem, and tebipenem,
each of which posesses distinct pharmacokinetic and pharmacodynamic properties [16].
Carbapenems have been a common treatment for P. aeruginosa because of its normal
inability to prevent their entrance, degrade, or efflux them to concentrations below the
minimum inhibitory concentration (MIC) [17].
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However, the resistance to the carbapenem impinem has been known to occur in
P. aeruginosa since at least 1989, and strains resistant to all carbapenems known as
carbapenem resistant P. aeruginosa (CRPA) have since emerged [18][19]. Owing to
the already limited permeability the P. aeruginosa outer membrane, mutational loss
of the porin OprD (D2) is sufficient to confer impinem reistance. β-metalloproteases
are rarely found, but capable of hydrolyzing carbapenems, and the extended-spectrum
cephalosporinases are also capable of limiting the effectiveness of carbapenems. Ef-
flux pumps, an innate factor of P. aeruginosa’s general antibiotic resistance, can be
overexpressed and contribute to carbapenem-resistance even in the absence of any
carbapenem-hydrolyzing enzymes [20].
The development of CRPA strains has contributed to a worrying prevalence of clinically
severe infections. Amongst antibiotic-resistant bacterial infections, CRPA-attributed
bacterial deaths in the European Union trail only methicilin-resistant Staphylococcus
aureus and third-generation cephalosporin-resistant Escherichia coli [21]. Indeed,
carbapenem-resistance itself has been tentatively-linked to increased mortality when
comparing P. aeruginosa and CRPA-mediated bacteremia [22].
When carbapenem fails to treat CRPA infection, antibiotics with more potent side-
effects such as polymyxin B and colistin (polymyxin E) are employed. Formerly consid-
ered too nephrotoxic for regular clinical use, carefully controlled doses of polymyxins
have been used effectively against CRPA. The positively-charged polymyxins can
mitigate CRPA’s innate and acquired defenses by binding to the negatively-charged
extracellular portion of Lipid A, passing through and acting in a detergent-like matter
which fatally disrupts the outer membrane [23]. Yet still, resistance to even these
‘last line of defense’ treatments has been observed, with one study identifying colistin
resistance in 21.3% of tested clinical isolates [24].
Recently, several clinical trials for antibiotics which could treat CRPA have taken
place. With few exceptions, it is primarily members of existing antibiotic classes
and combinatorial treatment with existing antibiotics that are in advanced stages of
development [25]. Murepavidin of the novel outer membrane protein-targeting antibiotic
(OMPTA) class has shown promising efficacy against CRPA, but resistance mechanisms
have already been observed within clinical isolates [26]. Given the demonstrated ability
of P. aeruginosa to develop resistance to the vast majority of existing antibiotics, it is
of the utmost importance that this repertoire be expanded as much as possible.
4 Introduction
1.4 Coenzyme A and the role of pantothenate ki-
nase
CoenzymeA [CoA] is a cofactor found in and necessary for all known organisms to
survive [27]. It consists of panothenate linked to both a 3’,5’-adenosine diphosphate and
a cysteamine. The cysteamine moiety of CoA can be acetylated by acyl-CoA synthetases,
producing the acetyl-CoA which serves as the acetyl carrier in the tricarboxylic acid
cycle of aerobic organisms [28]. Acetyl-CoA is also a necessary component in fatty acid
synthesis, where it is utilized directly by both fatty acid biosynthesis enzyme H (FabH)
and the acetyl-CoA carboxylate complex (ACC) as initial steps of the synthesis pathway.
Further modification of these fatty acids produces glycerolipids, key components of the
cellular membranes found in both Gram-positive and negative bacteria [29]. Beyond
that, CoA and compounds originating from CoA are estimated to be involved in at
least 4% of all reactions within E. coli [30].
The biosynthesis of CoA is a multi-step process involving several enzymes, and despite
often vast differences in amino acid sequence the overall pathway has remained conserved
[31]. The first and rate-limiting step involves the phosphorylation of pantothenate (Fig-
ure 1.1) by pantothenate kinase (PanK), which produces the 4’-phosphopantothenate
utilized later in the CoA synthesis pathway [27].
Fig. 1.1: Pantothenate, the substrate of PanKs including PaPanK, the phosphorylation of which is
a vital step of CoA synthesis.
Three different types of bacterial PanKs are known to exist. In type I, the functional
protein exists as a tetramer consisting of 4 identical subunits. Type I PanK is found
only in Eubacteria and is encoded for by the coaA gene [32]. The type II and III PanKs
exist as dimers, with type II being found in eukaryotes and a few bacterial species
such as Staphylococcus aureus. All known type III PanKs and some type II PanKs
are notable for their lack of feedback inhibition by CoA or its thioesters [33]. Type
III PanKs represent the most recently classified isoforms of PanK and are encoded for
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by the coaX gene. In contrast to type I and type II isoforms, type III PanKs have a
closed substrate binding pocket and bind ATP much more weakly [34].
One such example of a type III PanK is the P. aeruginosa PanK (PaPanK), the
sole protein exhibiting PanK activity in P. aeruginosa. It has been shown that in
addition its typical requirement of Mg2+ for ATP binding, its open ATP binding pocket
necessitates the presence of a singly charged cation for phosphorylation to occur. The
activity of PaPanK is nearly zero when only Na+ or Li+ cations are used, with the
presence of any of K+, Rb+, or NH4+ strongly preferred [35]. While PaPanK’s affinity
for pantothenate (KM=5 μM) is similar to the type I and II PanKs, it has a much
lower affinity for ATP (KM=7.3 mM). Given the extremely high concentration of ATP
required for phosphorylation of pantothenate, Hong et al. (2006) tested the activity
of PaPanK with a variety of alternative nucleotide phosphoryl donors and found that
similarly high concentrations were required regardless of the phosphoryl donor used. In
the same work, the structures of Se-Met PaPanK and Se-Met PaPanK-Pantothenate
(Figure 1.2) were determined, with pantothenate seen binding at the dimer interface
[35].
Fig. 1.2: The pantothenate-binding active site of Se-Met PaPanK-pantothenate reproduced from
PDB 2F9W, showing the hydrogen bonds (dashed lines) between pantothenate (labelled PAU) and
the surrounding protein residues. The two protein chains are colored differently.
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1.5 PaPanK as a target for antibiotics
Antibiotics made to target specific species of pathogenic bacteria are highly appealing,
as they can target necessary biological mechanisms to which there exists no known
resistance. Additionally, such antibiotics could be less disruptive to the surrounding
microbiome than traditional broad-spectrum antibiotics due to their species-specificity
(note: need to access paper on campus before citing)[36]. Perhaps most importantly of
all, species-specific antibiotics would avoid the risk of over-use that greatly contributes
to the development of antibiotic resistance. Based in part on a binding pocket analysis
of both solved and unsolved protein structures by Sarkar and Brenk (2015), PaPanK
was selected as a target for drug development [37]. A number of studies have found the
coaX gene encoding PaPanK to be essential for P. aeruginosa [38][39][40]. Further,
coaX from P. aeruginosa has been shown to rescue coaBC knockout E. coli [41].
Pantothenate kinase inhibitors have previously been developed against type I and
type II isotypes, but such compounds have been show to bind type III PanKs only
weakly or not at all. In addition to the lack of amino acid identity, Guan et al. (2010)
attribute this to the aforementioned closed substrate binding pockets of type III PanKs.
This steric hindrance prevents known inhibitors of type I and type II PanKs, such as
pantothenamides, from binding to the active site [42].
1.6 Fragment screening
There exists no practical way to test all potential inhibitors in a laboratory setting
given the existence of a vast number of compounds. Thus, diverse low molecular weight
chemical libraries have been designed to probe binding pockets more efficiently than
larger (~450 Da) drug-sized molecules. According to Edfeldt et al. (2011), testing a
library of 1000 compounds under 200 Da can be as informative as a library consisting
of 10 trillion drug-sized compounds [43]. The small size of these fragments reduces
the chances of steric hindrance as well as excessive hydrophobic interactions from
interfering with the screening process. While this means that smaller fragments can
be used to effectively probe target sites and assess the abilities of different functional
groups to interact with key residues, it also means that hits from a fragment screen
tend to bind much more weakly than therapeutic drugs [44]. It is for this reason that
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further refinement of initial fragment screening hits is often necessary to elicit stronger
binding. Shuker et. al. (1996) demonstrated the additivity of changes in Gibb’s
free energy (ΔG) when two or more weakly-binding fragments are covalently linked,
resulting in binding that is more energetically favorable and thus significantly stronger
than either individual fragment alone. As long as the linked fragments can occupy
adjacent spaces simultaneously, the small fragments can be combined into drug-sized
molecules without the inefficient and costly process of screening drug-sized libraries
[45]. Owing to the difficulty of linking fragments while retaining the binding modes of
the original compounds and the difficulties of screening drug-sized compounds, it is
increasingly common to gradually modify fragment screening hits through trial and
error to discover drug-candidates (Figure 1.3) [46].
(a) Drug-sized compound binding (b) Fragment-based drug design
Fig. 1.3: Fragment-based drug design versus drug-sized, high throughput screening. (a) Large,
drug-sized compounds (orange) are less efficient at probing the active site of the protein (blue) due to
an increased likelihood of forming non-favorable interactions. Hit rates from screening such compounds
are very low, but can have much higher affinities if the number of non-favorable interactions is limited.
(b) Fragment-based drug design relies on screening of small compounds to identify scaffolds (1) which
can be chemically altered or enlarged (2, 3) to achieve strong binding.
Identification of these weakly-binding compounds from a fragment library requires
techniques which are both sensitive and, ideally, high-throughput. One such method-
ology is bio-layer interferometry (BLI). Using BLI, molecules of interest (including
proteins) can be adsorbed onto sensor probes in various manners depending on the
sensor surface coating before exposure to solvents containing molecules of interest
(Figure 1.4). The fiber-optic sensors transmit white light through the pins down to the
coated sensor tips, where it is reflected both at the interface of the fiber – bio-layer
interface and the interface between the buffer and any bound molecules. The degree of
interference from these two reflected beams of light depends on the added thickness of
the bound molecules and can be used to detect the interactions between proteins and
low molecular weight ligands. The signal contribution of non-specific binding can be
mostly be accounted for by using a parallel set of reference sensors to which a quenching
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Fig. 1.4: Bio-layer interferometry sensor visualization. The target of interest is adsorbed onto the
attachment layer, which can consist of Ni2+, streptavidin, or otherwise. The sensor is exposed to an
analyte solution containing the compounds of interest, and light is passed through the fiber optic
sensor. Binding to the adsorbed target changes the way light is reflected at the analyte solution -
target interface, and results in a measurable change in interference with the light reflected by the
internal reference layer. Figure created with Biorender.
compound is adsborbed. In the case of streptavidin-coated BLI sensors, this quencher
can be either biotin or biocytin. In comparison to the more commonly used label-free
technique of surface plasmon resonance (SPR), changes in the refractive index interfere
less with BLI measurements [47]. Although BLI measurements with the Octet Red384
(ForteBio) are on the order of 10-fold less sensitive than with SPR instruments, it has
been shown to be an effective fragment-screening tool for compounds >150 Da. [47][48].
In this thesis, fragment screening experiments were conducted using the similar but
smaller-scale Octet Red96 (ForteBio).
A virtual screen as conducted by Lee (2020) for potential inhibitors of PaPanK identified
primarily compounds with a carboxylate group [49]. In the simulated binding modes
the carboxylate was seen to interact with Tyr92, Gly99, Arg102, and Thr180, similarly
to the carboxylate of pantothenate (Figure 1.2). Therefore, these compounds plus an
additional 305 compound library consisting solely of carboxylate-containing fragments
were utilized in this work in the hopes of observing active-site specific binding.
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1.7 X-ray crystallography
X-ray crystallography is an invaluable method for determining the 3D structures of
proteins, in which crystallized proteins are subject to powerful X-ray beams in order to
produce solvable diffraction patterns. This methodology requires that the molecule(s)
of interest first be formed into orderly crystal structures with regularly arranged unit
cells. The X-ray beams used are of similar wavelengths to short atomic bond lengths, ~1
Å. The unit cell determines the scattering of the beams, while the layout of individual
atoms within these unit cells determines the intensity of reflected beams [50]. Only
diffracted beams which are in phase produce the constructive interference needed
for detection. This only occurs when Bragg’s Law (1.1), relating a whole number of
wavelengths (nλ), distance between diffraction points (d), and beam angle relative to
the lattice plane (sin(θ)) is fulfilled [51].
nλ = 2dsin(θ) (1.1)
In order to resolve these diffraction patterns into a 3D structure, the phase must
also be determined as phase is a necessary component of the fourier synthesis used
to map electron density [52]. As mentioned earlier, Se-Met PaPanK crystals have
been previously diffracted both as an apo-enzyme (PDB 2F9T) and in complex with
panothenate (PDB 2F9W), with selenomethionine replacing all 6 methionine residues
[35]. The presence of selenium in these residues produces anomalous, highly intense
signals in the crystal diffraction patterns and is often utilized in solving the phase
problem [53].
Dauter (1999) discusses the underlying principles of data collection from crystals when
X-rays of a single wavelength are applied, as is typically performed for structural
determination. Whether an atom reflects an X-ray beam depends on its position in
an Ewald sphere of radius 1/λ - only reciprocal lattice points along the edge of this
sphere will satisfy Bragg’s Law, resulting in a reflected beam which can be picked up by
the detector and contribute to the overall diffraction pattern. At a single wavelength,
the Ewald sphere remains constant and thus rotation of the crystal during exposure
to the X-ray beam is necessary. Rotation of the crystal brings different reciprocal
lattice points to the surface of the Ewald sphere, and with enough rotation enough
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reflected beams can be measured to map the electron density of an entire protein. The
amount of rotation necessary depends upon the crystal geometry, derived from the
space group, as this determines which reciprocal lattice points will lay upon the edge
of the Ewald sphere during beamline operation [54]. While crystals can be rotated in a
helical manner or imaged serially from entirely separate crystals to reduce the impact
of radiation damage, rotating about a single point is commonplace [55] [56].
The formation of protein crystals is itself a process of trial and error. The ultimate
goal of such trials is to coax the protein of interest into super-saturated state that
favors crystal nucleation, followed by growth [57]. The sitting-drop vapor diffusion
method is widely used to produce protein crystals, where the protein of interest is
added at a specific concentration to a drop of a given pH, precipitant, salt, and any
other desired additives. The drop is sealed, sitting above a chamber containing the
same precipitating buffer. By sealing this environment from outside air, vapor gradually
diffuses and initially dehydrates the protein-precipitant drop, potentially leading to
super-saturation and crystal formation before equilibrium is reached [58]. Each of the
aforementioned drop contents affect the outcome, and the exact conditions required are
unpredictable hence the typical need for many trials. If the protein is over-saturated,
disordered aggregates or films can form which are not useful for structural determination.
Undersaturation means that the solubilized state remains energetically favorable, and
crystals can neither form nor grow. If conditions are energetically favorable for crystal
growth, these crystals will continue to grow faster than they dissolve until reaching
equilibrium, where crystal growth and dissolution rates are equal [59].
Chapter 2
Aims
The overarching goal of this work was to identify starting points in the drug discovery
of new antibiotics which could be used to treat carbapenem-resistant P. aeruginosa
infections by inhibiting PaPanK. BLI was used to screen a large number of compounds,
both from fragment libraries and a structure-based virtual screen, in order to iden-
tify those which possessed the highest affinities for PaPanK. PaPanK needed to be
biotinylated for use with this system, and expressed in large enough amounts for many
assays to be performed. The development of methods to reliably obtain well-diffracting





The components of all non-purchased buffers were weighed out using a Sartorius Pro
32/34F Balance (Sartorious) for masses greater than 0.5 g, and an AB104-S (Mettler
Toledo) scale for smaller amounts. Buffers were then pH adjusted using NaOH and HCl
solutions using a magnetic stir bar and a 780 pH Meter (Metrohm). Buffers to be used
on the ÄKTA Pure 25 (Cytiva) instrument were filtered using a vacuum apparatus
with MF-Millipore™ Membrane Filters, 0.22 µm pore size (Merck).
3.2 SDS-PAGE
Visual evaluation of protein purity and size was performed via SDS-PAGE, typically
using Any kD Mini-PROTEAN TGX Precast Protein Gels (Bio-Rad) and occasionally
4-20% Mini-PROTEIN TGX Precast Protein Gels (Bio-Rad) when Any kD gels were
unavailable. A Precision Plus Protein™ Dual Xtra or Dual Color Standard (Bio-Rad)
was used for size comparison in each gel. Samples were mixed with a 6X Laemmli
loading dye [60] followed by heat-denaturation at 95 °C for 5 minutes prior to loading.
A constant 100 V current was applied for 10 minutes, increasing to 150 V for an
additional 20-30 minutes. Gels were stained per manufacturer instructions using either
25 mL InstantBlue Protein Stain (Expedeon) or PageBlue Protein Staining Solution
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(Thermo Scientific). Imaging took place on a ChemiDoc XRS+ System (Bio-Rad) with
exposure set to automatic and with no filters in place.
3.3 Plasmids utilitized
All plasmids arrived pre-assembled and ready for transformation. 6HisTevPaPanK
was contained in a pET-28a(+)-TEV (Genscript) vector as described in Lee (2020)
[49]. 6HisAviPaPanK was contained in a near-identical pET-28a(+)-TEV vector, with
the addition of an AviTag [61] encoding amino acids GLNDIFEAQKIEWHE and a
GS linker just prior to the PaPanK sequence. GST-BirA consisted of a gluthione-S-
transferase affinity-tag linked to E. coli biotin ligase, contained in a pGEX-6P-1 vector
donated by Petra Hänzelmann (University of Wuerzburg).
3.4 Transformation of E. coli with 6HisTEVPaPank
and 6HisAviPaPanK
The early stages of production of 6HisTEVPaPanK and 6HisAviPaPanK were identical
except for the plasmid used. 1 μL of 40 ng/μL of the appropriate plasmid was added
to 100 μL of C43(DE3) cells (Lusigen) on ice, and stirred with the pipette tip. Cells
mixed with the plasmid were then incubated on ice for 30 minutes and subsequently
heat shocked at 42 °C in a water bath for 45 seconds. Cells were then placed on ice
for 2 minutes, and 950 μL room temperature Recovery Medium for Expression (Sigma
Aldrich) was added. Tubes of cells were placed on a Thermomixer Comfort (Eppendorf)
shaker at 250 rpm for 1 hour at 37 °C. Agar plates were prepared using autoclaved LB
agar (10 g tryptone, 5 g yeast extract, 5 g NaCl, 15 g agar per liter). LB-agar was
microwaved until completely liquefied and allowed to cool to below 70 °C before the
addition of 50 μg/mL final kanamycin. Plates were poured roughly 1 centimeter deep
and allowed to solidify, and 100 μL of transformed cells were spread onto the plates in
close proximity to an open flame. Plates were sealed with parafilm and left to incubate
overnight at 37 °C.
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3.5 Glycerol stock preparation
A single transformed bacterial colony was inoculated into 50 mL of autoclaved LB
medium (10 g tryptone, 5g yeast extract, 5 g NaCl per liter) containing the plasmid-
specific antibiotic by leaving a coated pipette tip in the LB medium. Inoculated LB
medium was incubated at 37 °C overnight with 200 rpm shaking, and a 1:1 v/v mixture
with autoclaved glycerol was prepared. 400 μL aliquots were made before flash freezing
with liquid nitrogen and storage at -80 °C.
3.6 Lysis and purification of recombinant PaPanK
cell pellets
Following pelleting of recombinant PaPanK bacterial cultures, lysis of each pelleted 1
L of original culture was performed at 8 °C by the addition of 30 mL of lysis buffer (20
mM Tris HCl pH 7.9, 500 mM NaCl, 20mM Imidazole, 10% (v/v) glycerol, 1 tablet
cOmplete, EDTA-Free Protease Inhibitor Cocktail Tablets (Roche) per 120 mL final
solution volume). A magnetic stir bar was placed inside and mixing took place at 500
rpm for 25 minutes. Dnase I (Sigma Aldrich) was added after 25 minutes to a final
concentration of 1 U/mL, and mixing continued for an additional 5 minutes. After
mixing, resuspended pellets were transferred to 50 mL falcon tubes. The samples
were then placed on ice and subjected to sonication at an amplitude of 20 W with
10 second intervals for 1 minute. After 1 minute of resting, samples were sonicated
for an additional 1 minute using the same settings. Following sonication, samples
were transferred to high-speed round bottom centrifuge tubes and spun down (15000
RCF, 15 minutes, 4 C). Supernatant was transferred into clean 50 mL tubes and then
syringe-filtered using Whatman Filter Units 0.2 uM (GE). Supernatant was then kept
on ice before IMAC using an ÄKTA Pure 25 (Cytiva).
Binding buffer was prepared with 20 mM Tris HCl pH 7.9, 500 mM NaCl, 20mM
Imidazole, 10% (v/v) glycerol, and an elution buffer was prepared with 20 mM Tris
HCl pH 7.9, 500 mM NaCl, 500 mM Imidazole, 10% (v/v) glycerol. The ÄKTA Pure
25 flow rate was set to 5 mL/min and a HisTrap HP 5 mL (Cytiva) column was
equilibrated with binding buffer. Filtered supernatant was then pumped onto the
16 Methods
column and washed with 5 CV binding buffer. A linear gradient elution transitioning
from 100% binding buffer to 100% elution buffer was applied to the column, and
eluant was collected in a Deep Well Megablock, 2.2 mL (Sarstedt) 96 well plate. UV
absorption was measured by the built in UV meter, and protein peaks were identified
through the UnicornEval (GE) software, using the appropriate extinction coefficient at
280 nm to determine yield and concentration. Protein fractions of interest were then
combined and concentrated to a volume of 5 mL or less using Amicon Ultracel Filter
Units (Millipore) with 10 kD size cutoffs, simultaneously buffer exchanging using gel
filtration buffer (50mM Tris HCl pH 7.5, 150mM NaCl).
Protein was then subject to Size-Exclusion Chromatography (SEC) using a HiLoad
26/600 Superdex 75 pg (Cytiva) column equilibrated with gel filtration buffer. Con-
centrated protein samples were loaded onto a loop attached to the ÄKTA Pure 25
system and the column was washed with 1.5 CV of gel filtration buffer. Flow through
was collected and the protein peaks were identified through the UnicornEval (GE)
software. Samples were then further concentrated and if necessary, buffer exchanged
using Amicon Ultracel Filter Units on a Centrifuge 5417R (Eppendorf) at 10,000 rpm
until the desired volume was obtained. Concentration was then measured in duplicates
or triplicates using the protein A280 function on a NanoDrop ND-1000 (Thermo Fischer
Scientific).
Some 6HisTevPaPanK designated for use in crystallography experiments was subject
to TEV protease cleavage and reverse His-Trap purification (Method 3.7). SEC was
omitted in such cases.
3.7 6His-tag cleavage and reverse His-Trap purifi-
cation
Following an initial His-trap purification of PaPanK containing a TEV site and a
His-tag, samples intended for cleavage were buffer exchanged to cleavage buffer (25 mM
Tris HCl pH 7.4, 150 mM NaCl). TEV protease was expressed and purified in-house
and stored in 50 mM Tris-HCl pH 7.5, 1 mM EDTA, 5 M DTT. TEV protease was
added at a 1 : 10 mass ratio to PaPanK in cleavage buffer and incubated overnight at
8 °C for 14-16 hours, rotating on an SB-3 Rotator (Stuart) set to 4 rpm. Samples were
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then immediately subjected to reverse His-trap purification in order to separate any
uncleaved protein and TEV protease from the desired cleaved protein.
A HisTrap HP 5 mL (Cytiva) column was equilibrated with binding buffer (20 mM
Tris HCl pH 7.9, 500 mM NaCl, 20 mM imidazole, 10% (v/v) glycerol), and TEV
protease treated samples were loaded using an ÄKTA Pure 25 (Cytiva). The column
was then washed with 5 CV of binding buffer and the flow through was collected.
Depending on the experiment, elution of any protein still bound to the column was
performed isocratically with 100% elution buffer (20 mM Tris HCl pH 7.9, 500 mM
NaCl, 500 mM imidazole, 10% (v/v) glycerol) or with a linear gradient transitioning
from 100% binding buffer to 100% elution buffer over 5 CVs. Fractions which showed
high UV absorbance were viewed using the UnicornEval (GE) software, and samples
were assessed for cleavage and purity by running SDS-PAGE. Concentration was
measured using a NanoDrop ND-1000, and 5% (v/v) glycerol was added prior to flash
freezing with liquid nitrogen. Cleaved protein was then stored at -80 °C.
3.8 GST-BirA expression and purification
The GST-BirA needed for enzymatic biotinylation of PaPanK used in the course
of this work resulted from the transformation of a pGEX-6P-1 vector provided by
Petra Hänzelmann (University of Würzburg) into Rosetta(DE3)pLysS E. coli cells.
Transformation, expression, and purification were performed as described by Fairhead
and Howarth (2015) [61].
A modified version of this protocol was performed in this work but not utilized for
enzymatic biotinylation of PaPanK, in which the same steps were followed until
lysed cells were pelleted and supernatant was collected. Using an ÄKTA Pure 25
(Cytiva) system, this supernatant was loaded onto a GSTrap FF 5 mL column (Cytiva)
equilibrated with PBS pH 7.3, 1mM DTT, 0.1% (v/v) Triton X-100. After equilibration,
sample was loaded at a flow rate of 4mL/min. The column was washed with 5 CV
of the same buffer at a 5 mL/min flow rate. Isocratic elution followed using 5 CV
of 50 mM Tris HCl pH 8.0, 10mM reduced glutathione, 1mM DTT, at a flow rate
of 5 mL/min and elution fractions were collected in a Deep Well Megablock, 2.2 mL
(Sarstedt) 96 well plate.
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3.9 Enzymatic biotinylation of 6HisAviPaPanK
Site-specific enzymatic biotinylation was performed based upon the protocol by Fairhead
and Howarth (2015) by incubating Avi-tagged PaPanK with E. coli biotin ligase (BirA).
This BirA included a GST-tag in order to facilitate its removal after biotinylation.
952uL of 100uM 6HisAviPanK in gel filtration buffer (50mM Tris HCl pH 7.5, 150mM
NaCl), 5uL 1M MgCl2, 50uL GST-BirA (1.45mg/mL stock), 3uL 50mM D-biotin (in
DMSO), and 5uL 400mM ATP were added to a 1.5 mL Eppendorf tube. The mixture
was incubated at 30 °C for one hour with 250 rpm shaking on a tabletop plate shaker.
In order to remove GST-BirA, 0.1mL of glutathione 50% slurry was added to the mix
and rotated for 1 hour at 8oC. The resulting mixture was then centrifuged (4 °C, 2
minutes, 2k RCF). A Zeba Spin Desalting Column (Thermo Fisher) was washed twice
with 2 mL of gel filtration buffer by centrifuging (4 °C, 2 minutes, 2k RCF). The
desalting column was then transferred into a new eppendorf and the protein mix was
added via pipette, avoiding the slurry mix. The protein was eluted by centrifuging (4
°C, 2 minutes, 2k RCF).
3.10 Bio-layer interferometry
Fragment screening of virtual screen hits and library fragments was performed using
the Octet RED 96 Bio-Layer Interferometer (ForteBio). Octet Super-Streptavidin
(SSA) Biosensors (ForteBio) were coupled with enzymatically biotinylated PaPanK,
taking advantage of the especially strong affinity of streptavidin for biotin. In Black
Sterile 96 Well F-Bottom Plates (Greiner), 200uL volumes were used per well to ensure
that sensor tips were adequately immersed. SSA Biosensor racks were set up with two
parallel columns of 8 sensors pre-soaked for 10 minutes in BLI running buffer (50mM
Tris-HCl pH 7.5, 150 mM NaCl, 50 mM NH4Cl, 5% (v/v) DMSO). One set of sensors
was designated for loading with biotinylated 6HisAviPaPanK while a parallel reference
set was designated for loading with biocytin (10 ug/mL). The instrument was set to
25oC.
During protein loading, sensors were serially exposed to a separate 96 well plate
containing columns of BLI buffer, biotinylated PaPanK, and biocytin. First, sensors
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(a) BLI sensor rack layout used in both protein load-
ing and ligand analysis experiments. Two parallel
columns of SSA biosensors are used, with those in
light blue exposed to biotinylated PaPanK before
quenching with biocytin. Yellow ’R’ (reference) sen-
sors skip the protein well and are only bound to bio-
cytin.
(b) BLI loading plate layout for preparing PaPanK
sensors and biocytin reference sensors. Wells labelled
’B’ contain BLI running buffer for equilibration, base-
line, and wash steps. ’L’ wells contain biotinylated
6HisAviPaPanK which is not applied to the reference
sensors. ’Q’ contains the quencher, biocytin, applied
to both the reference and protein-loaded sensors/
Fig. 3.1: Bio-layer interferometry sensor arrangement and well-layout for loading of sensors with the
target protein and biocytin controls. The images were taken from the FortéBio Data Analysis 9.0
software.
were equilibrated for 300-1200 seconds with the BLI buffer, followed by a 60 second
baseline step. Next, biotinylated PaPanK was bound to one column of sensors for
300 seconds. Next, sensors were transferred to biocytin for 60 seconds in order to
quench any remaining unbound streptavidin molecules. A wash step proceeded for 60
seconds followed by a final 60 second baseline step. The reference sensor column was
not exposed to biotinylated PaPanK.
3.10.1 Protein loading optimization
The determination of the concentration of biotinylated PaPanK necessary for eliciting
a response > 5 nm was performed by testing a range of concentrations from 12.5 to
250 ug/mL. Enzymatically biotinylated PaPanK (varying from 25 to 100 ug/mL) was
bound to SSA biosensors in BLI running buffer (50mM Tris HCl pH 7.5, 150mM NaCl,
5% (v/v) DMSO, 50mM NH4Cl).
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Fig. 3.2: Plate layout for fragment screening at a single concentration. When fragment screening
at 2 concentrations with virtual screen compounds, alternating wells would be included at 2500 μM.
Rows A and H serve as reference-wells without added screening compounds to correct for sensor drift
and background buffer signals. Columns 1 and 12 are also free of screening compounds and are used
for the baseline and dissociation steps, respectively.
3.10.2 Compound binding
Fragment library compounds and virtual screen hits to be measured for KD determina-
tion and PaPanK specificity arrived in 100% DMSO. For fragment screening of library
compounds at a single concentration, a Mosquito HV was used to transfer 10 μL of
compounds into a 96 well plate. The same DMSO concentration was maintained in
all wells. 190 μL of DMSO-free BLI running buffer was added to all wells to which 10
μL of DMSO-solubilized compounds were added. During fragment screening and hit
validation of the carboxylic acid library and EU-OPENSCREEN (EU-OS) libraries,
0.01% (v/v) Triton X-100 was included in all wells. During hit validation, samples
were pipetted manually and multiple 2-fold or 3-fold serial dilutions were performed
for KD determination. Water-solubilized samples such as pantothenate and ATP were
first diluted from stocks into BLI running buffer before addition to 96 well plates,
maintaining the 5% (v/v) final DMSO concentration.
BLI data processing
Data from the Octet RED 96 instrument were analyzed using the FortéBio Data
Analysis 9.0 software. Compound identities, concentrations, and protein/biocytin
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sensors and reference wells were defined. Double-referencing was selected to subtract
the the biocytin and reference well responses from the protein responses. Baseline
alignment was selected, Savitzky-Golay filtering (smoothing) was turned on, and the
data were processed. For KD determination, the built-in steady state model was applied
using association step response values from 20-25 s or 50-55 s, depending on if the
association step was 30 or 60 s.
For primary screening of the carboxylic acid and EU-OS libraries, biocytin and PaPanK
sensor responses were only referenced against the buffer-only reference wells. The
corrected biocytin sensor responses and PaPanK sensor responses were filtered within
KNIME for each compound. A workflow in KNIME filtered these inputs by first
excluding all samples with a biocytin response greater than 0.1 nm or less than -0.1 nm.
The mean biocytin response ± 1 STD was calculated for the remaining compounds and
any which exceeded the upper bound or were below the lower bound were excluded.
Lastly, the mean PaPanK response - biocytin response + 1 STD was calculated and
only compounds above this threshold were considered hits. These hits were subject
to visual evaluation of the PaPanK response curves, with slow-binding compounds
excluded.
3.11 PaPanK crystallization, ligand soaking, and
structural determination
Crystallization of intact 6HisTevPaPanK following SEC purification was attempted by
first concentrating the protein to 22 mg/mL in gel filtration buffer (50mM Tris HCl pH
7.5, 150mM NaCl) using Amicon 10k filter units. A Mosquito HV was used to prepare
sitting drops on Triple Sitting Drop 96-well plates (TTP Labtech) with JCSG-plus,
PACT Premier, Morpheus, and Ligand Friendly screens (Molecular Dimensions). 50
μL of precipitant from each kit was manually pipetted into the reservoir wells. The
Mosquito was used to create drops containing 100, 150, or 200 nL of reservoir-well
precipitant and the amount of protein necessary to bring the final drop volume to 300 nL.
One of each screen was prepared for storage at 20 °C and the plates were automatically
imaged with a Rock Imager 182 (Formulatrix). Additional plates prepared with the
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Morpheus, JCSG-plus, and Ligand Friendly screens were stored at 8 °C and manually
examined using optical microscopy.
Aliquots of frozen TEV-cleaved PaPanK from a previous master’s student were thawed
and concentrated using 50 mM Tris-HCl pH 7.5 and optimized based on well E12
of the JCSG Plus screening plate (100 mM imidazole pH 8.0, 10% (w/v) PEG8000).
Optimization of sitting drops based on a reproduction of this buffer was performed
by varying pH, drop ratios, and input protein concentrations. In addition to varying
well buffers and protein concentrations, 3 different drop ratios were used (100 nL
protein:200 nL precipitant, 150 nL protein:150 nL precipitant, and 200 nL protein:100
nL precipitant) for a total of 288 conditions. The plate was stored and imaged at 20
°C. Further crystallization experiments utilized TEV-cleaved PaPanK expressed and
purified during this thesis, with 100 mM imidazole pH 8.0, 8% (w/v) PEG8000, 150
nL protein:150 nL precipitant, and 17 mg/mL PaPanK in 50 mM Tris-HCl pH 7.5
stored at 20 °C.
3.11.1 Cryoprotectant selection
Protein crystals to be subjected to X-ray diffraction were cryoprotected prior to freezing
in liquid nitrogen. Determination of cryoprotectants which did not dissolve or visually
deform the crystals was performed using cryomixes (CM) from the CryoSol™ MD1-
90 kit (Molecular Dimensions). These cryomixes contain several varying types and
concentrations of cryoprotective compounds. Cryoprotective solutions of CM-1 through
CM-9 were produced per manufacturer instructions using 50% (v/v) 2X crystallization
precipitant, 40% (v/v) cryomix solution, and 10% (v/v) 10X crystallization buffer.
Thereafter, 0.5 μL of the soaking solutions were added to various crystals and any
visible changes to crystal structures were recorded after 21 hours. The predominantly
used cryoprotectant was CM-3, which prior to dilution contained 25% (v/v) 2-methyl-
2,4-pentanediol (MPD), 12.5% (v/v) 1,2-propanediol, 12.5% (v/v) DMSO, 12.5% (v/v)
glycerol, 12.5% (v/v) ethylene glycol, and 25% (v/v) water.
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3.11.2 Soaking of PaPanK crystals with ligands
Soaking of crystals in a cryoprotectant-ligand solution was performed after crystal
formation in order to later diffract PaPanK crystals with ligands bound to the individual
proteins making up the lattice. The chosen CM solutions from Method 3.11.1 were
altered by making them with 32% (v/v) 3.125X crystallization precipitant and replacing
the additional 18% volume with the ligand of interest. If the ligand was ATP or another
nucleotide, up to 20 mM Mg2+ and 80 mM K2+ were included in the mixture. 0.5-0.8
μL of these soaking solutions were pipetted directly into crystal-containing drops and
allowed to soak for up to 6 hours before fishing with loops and flash-freezing with
liquid nitrogen.
3.11.3 Alternative soaking of PaPanK crystals with ligands
Alternatively, crystals were soaked using a cryomix-free solution which contained 32%
(v/v) 3.125X crystallization precipitant, 10% (v/v) 10X crystallization buffer, and
36% (v/v) water, with the remaining 22% volume reserved for the ligand(s) of interest.
Ligands dissolved in DMSO were limited to 8% (v/v) in the soaking solution. 0.8 μL
of these soaking solutions were pipetted directly into the crystal-containing drops and
allowed to soak for up to 6 hours. Thereafter, crystals were fished and briefly dipped
into a drop of cryoprotective solution containing CM-3 (40% (v/v) CM-3, 32% (v/v)
3.125X crystallization precipitant, 10% (v/v) crystallization buffer, 18% (v/v) water)
before flash-freezing with liquid nitrogen.
3.11.4 Structural determination and refinement of X-ray data
To produce molecular models from diffracted crystals of apo-enzyme PaPanK and
PaPanK-Pantothenate, Se-Met PaPanK (PDB 2F9T) and Se-Met PaPanK-Pantothenate
(PDB 2F9W) were used as reference models in the DIMPLE pipeline from CCP4i2.
These models were subject to manual correction using Coot, while Refmac5 was used to
improve agreement between the X-ray data and the molecular models. For modelling
and refinement of the PaPanK-ATP and PaPanK-B1 diffraction data, the model
produced by the PaPanK crystal diffracted during this work was used as the reference
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model. Refinement of the PaPanK-ATP and PaPanK-B1 was not fully completed.
The relevant data and statistics are shown in Appendix Table A.1.
3.12 Work contributed by others
The refinement of X-ray diffraction data was performed by Charis Georgiou. Vladyslav
Yadrykhinsky produced the KNIME workflow utilized in fragment screening analysis.
Khanh Kim Dao expressed and purified the TEV protease used for tag cleavage.




4.1 Expression and Purification of 6HisAviPaPanK
One aim of this thesis is to identify small compounds with PaPanK specificity that
could later be used to develop antibiotics. To screen large numbers of compounds, BLI
was utilized. In order to obtain PaPanK which could be loaded onto the SSA sensors
during BLI 6HisAviPaPanK needed to be expressed, as it contains a 15 amino acid
tag necessary for site-specific enzymatic biotinylation by E. coli Biotin Ligase (BirA).
Following transformation into E. coli C43 (DE3) cells, a number of well-isolated colonies
were observed growing on antibiotic-containing LB agar plates, which were successfully
used for the preparation of glycerol stocks and IPTG-induced overexpression. After
following the method described in “Lysis and purifcation” through to the His-trap
column purification, a narrow peak was observed and collected in the gradient elution
step at 40% elution buffer (Figure A.1), denoted as peak B. Based on the built-in UV
meter and the A280 0.1% of 0.826, a total of 36.50 mg of 6HisAviPaPanK was present
in this peak.
The elution fractions from peak B from the His-Trap column were further processed
as described in “Lysis and purification” and SEC was performed in order to isolate
6HisAviPaPanK based on size (Figure A.2). Two small peaks followed immediately
by a larger peak were observed, and this large peak C was suspected to contain the
purified protein. Owing to the proximity of peaks A and B, the elution wells which
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overlapped were not included when pooling the suspected protein fractions. According
to the built-in UV meter and the 0.826 A280 0.1%, this peak contained 15.01 mg of
protein, equal to 7.50 mg of purified protein per liter of E. coli culture. The total
protein yield according to Nanodrop was 14.93 mg, corresponding to a yield of 7.46
mg per liter of cultured E. coli. SDS-PAGE was performed in order to assess the
size and purity of the protein (Figure 4.1). One prominent band appeared in Lane 2
Fig. 4.1: SDS-PAGE after staining with PageBlue. Lanes 1 and 3 contain Precision Plus Dual Color
Protein Standards, with the labelled bands denoting size in kDa. Lane 2 contains the pooled contents
from SEC elution suspected to contain 6HisAviPaPanK
between the 25 and 37 kDa ladder markers, consistent with the expected 31.4 kDa size
of 6HisAviPaPanK. With the size confirmed, the protein was deemed pure enough to
attempt enzymatic biotinylation.
In order to uniformly biotinylate the Avidin-tagged PaPanK for use with BLI,
enzymatic biotinylation was performed using E. coli Biotin Ligase (BirA) as described
in Method 3.9. The success or failure of biotinylation was later assessed by loading to
the SSA sensors during BLI.
4.2 BLI with PaPanK
4.2.1 Protein loading optimization
Assessment of the binding of small molecules to the biotinylated 6HisAviPaPanK first
requires coating of the BLI sensors with the biotinylated protein of interest. SSA sensors
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were used due to their higher binding site density compared to the manufacturer’s
traditional streptavidin sensors, thus allowing for more biotinylated protein to be
bound. A balance between high sensor binding and minimal protein usage was desired,
and a range of protein concentrations were tested as described in Method 3.10.1 At each
concentration, protein was loaded onto SSA sensors as duplicates except for 100 μg/mL,
which was loaded onto only one sensor to accommodate a control sensor exposed only
to buffer.
After 300 seconds of exposure to various concentrations of biotinylated 6HisAviPaPanK,
response curves were produced (Figure 4.2). Responses increased with increased
protein concentration and no-protein controls elicited minimal responses. Protein
concentrations ≥ 25 μg/mL were deemed suitable for use in future binding analysis
experiments, and 25 or 100 μg/mL biotinylated 6HisAviPaPanK was used for loading
in all subsequent BLI experiments.
Fig. 4.2: Protein loading confirmation of biotinylated 6HisAviPaPanK onto streptavidin sensors
for BLI experiments. 1) Baseline step as a point of reference during analysis 2) Protein association
step with variable PaPanK concentrations. 3) Dissociation step where sensors were transferred to
protein-free buffer wells. The flat, nearly 0 nm response line comes from a sensor not exposed to
biotinylated 6HisAviPaPanK.
4.2.2 Establishment of ATP and pantothenate binding
In order to determine the suitability of BLI for identifying the binding of ligands to
PaPanK, KD determination of ATP and pantothenate was performed. As described
in Introduction 1.4, ATP and pantothenate have been previously shown to bind to
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(a) ATP duplicates BLI response.
(b) ATP duplicates KD=17 ± 1.6 mM,
n=2
(c) Pantothenate duplicates response.
(d) Pantothenate duplicates KD=2.5 ±
0.16 μM, n=2
Fig. 4.3: Combined duplicates of ATP and pantothenate BLI responses and calculated KD values
showing saturation with increased ligand concentrations. Figures (a) and (c) show double referenced
responses for ATP and pantothenate through association steps (0-60 s) followed by dissociation (denoted
by vertical red line). Figures (b) and (d) show the fitted lines of duplicate ligand concentrations
versus response values from steady state analysis. Error was calculated from the individual steady
state curves.
PaPanK with respective KM values of 7.3 mM and 5 μM. Protein was loaded onto
the sensors using 100 μg/mL and reached consistent responses of 10 nm. 5% (v/v)
DMSO was included in all baseline, association, and dissociation wells since this would
be present during the subsequent screening of the DMSO-solubilized fragments. KD
determination was performed according to Method 3.10.2 with ATP and pantothenate
tested in duplicates, with each replicate row being exposed to different protein-loaded
sensors and biocytin-loaded controls. 7 2-fold dilutions were performed, beginning from
100 μM pantothenate and 120 mM ATP.
In each duplicate set, the sensor response to each ligand increased as concentration
increased before flattening out as the maximum concentrations were approached, and
response values and fit curves were generated for ATP and pantothenate (Figure
4.3). Duplicate response values for each ligand were highly consistent and produced
well-fitting steady state curves, with R-squared values of 0.994 for pantothenate (Figure
4.3 d) and 0.987 for ATP (Figure 4.3 b). The experimental KD values when combining
duplicates of pantothenate and ATP were 2.5 μM and 17 mM respectively, versus
the literature KM values of 5 μM and 7.3 mM. While the KD value of pantothenate
indicated much higher affinity for the biotinylated PaPanK sensors than ATP, the ATP
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responses were notably much larger. ATP also did not appear to dissociate completely
at concentrations over 40 mM (Figure 4.3 a). Based on the behavior of pantothenate,
it was selected for continued use as a positive control during forthcoming fragment
screening and hit validation experiments.
4.2.3 Testing of virtual screening hits
A virtual screen conducted by Lee (2020) identified a number of compounds which
were predicted to bind to the active site of PaPanK, as described in 1.6. 17 of these
compounds were purchased and subsequently solubilized in DMSO for use in BLI. The
decision was made to conduct fragment screening of these compounds twice at different
pH values (pH 6.0 and pH 7.5) in case pH 7.5 did not support the protonation states
necessary for certain compounds to bind. The pH 6.0 buffer was identical except for
the use of 50 mM Bis-Tris Methane pH 6.0 in lieu of the Tris-HCl used in previous
BLI experiments (50mM Tris HCl pH 7.5, 150mM NaCl, 5% DMSO, 50mM NH4Cl).
Sample sensors were loaded with 25 μg/mL PaPanK and reached response levels of 7
nm at pH 7.5 and 10 nm at pH 6.0. The 17 virtual screen compounds were prepared
at concentrations of 2500 μM and 500 μM. 60 s baseline, 60 s association, and 60 s
dissociation steps were used and the screening was conducted at the two pH values.
Sample ID 500 μM Response (nm)pH 7.5
500 μM Response (nm)
pH 6.0
2500 μM Response (nm)
pH 7.5
2500 μM Response (nm)
pH 6.0
a1 0.113 0.0087 0.1675 0.0277
a2 -0.0373 -0.0225 -0.0729 -0.0593
a3 0.0031 0.0916 0.0811 0.2599
a4 -0.0078 0.0078 -0.0272 0.0075
b1 0.1541 0.0272 0.2732 0.1491
b2 -0.0323 -0.0216 -0.0204 -0.0754
b3 0.0069 0.0006 0.0943 0.0126
b4 0.0234 -0.0026 0.0365 -0.0044
c1 0.0272 0.0042 0.0082 0.0181
c2 0.0213 -0.0056 0.1111 -0.0162
c3 -0.036 0.0193 -0.0523 0.0976
d1 0.0781 0.0162 0.1322 0.0293
d2 -0.0149 0.0287 -0.0353 0.1608
d3 0.0122 0.0328 0.0522 0.1409
e1 -0.0341 0.0246 -0.0231 0.1383
e2 0.025 -0.0361 0.1342 -0.0829
e3 0.0197 -0.0063 0.0465 -0.0467
Table 4.1: Double-referenced BLI responses following 2-point screening of 17 virtual screen compounds
at pH 6.0 and pH 7.5. Compounds with highlighted response values were designated for further hit
validation based on their response values.
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Responses from the PaPanK sensors and the biocytin sensors were recorded and double
referencing was applied using the FortéBio Data Analysis 9.0 software according to
Method 3.10.2. These corrected response values were reviewed and compounds were
selected for further hit validation based on response intensity (Table 4.1). Notably,
response values varied considerably depending on the pH, with only two compounds
showing responses > 0.05 nm at both pH 6.0 and pH 7.5 (Table 4.1 b1, d3). Several
compounds showed negative responses at one or more pH, with a few becoming
significantly more negative with increased concentration (Table 4.1, a2, a4, b2, c2, c3,
d2, e2, e3). 11 compounds showed response values greater than the chosen cutoff of
0.05 nm at 2500 μM in at least one pH value. One of these compounds (Table 4.1, a3)
was subsequently excluded based on a linearly increasing response during association
and near-complete lack of dissociation from the sensor. The remaining compounds
(Table 4.1, a1, b1, b3, c2, c3, d1, d2, d3, e1, e2) were considered candidates for further
hit validation.
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Virtual screen hit validation
In order to determine the KD of the 10 virtual screen compounds narrowed down in
Section 4.2.3, 10 2-fold serial dilutions from 2500 μM to 4.88 μM were prepared prior to
BLI. While there was little overlap in responses at different pH values from the virtual
screening compounds, all 10 compounds were hit-validated at both pH 6.0 and pH 7.5
owing to the small amount of scale-up required. PaPanK was loaded at 25 μg/mL and
the PaPanK exposed sensors reached 11 nm response at pH 6.0 and 7 nm response at
pH 7.5. This pH or buffer-dependent variation in protein loading response was also
observed in Section 4.2.3. The serially diluted compounds were then screened with 60
s baseline, 60 s association, and 60 s dissociation steps.











a1 0.0292 5.70E-03 0.9875 0.1228 3.20E-04 0.995
b1 0.0872 1.50E-02 0.9961 0.1206 4.10E-04 0.9843
b3 -0.0011 3.50E+11 0.649 0.0098 4.20E-04 0.6755
c2 -0.013 <1.0E-12 0 -0.0362 <1.0E-12 0
c3 0.0432 <1.0E-12 0 0.0143 1.60E-03 0.7056
d1 0.0216 1.40E-02 0.9921 0.0896 9.40E-04 0.9828
d2 0.0551 1.20E+12 0.9406 0.079 8.50E-03 0.9915
d3 0.0599 <1.0E-12 0 0.1383 1.80E-02 0.9885
e1 0.0636 5.60E-02 0.967 -0.011 - -
e2 -0.0443 2.00E-05 1 0.093 9.90E-04 0.9625
Table 4.2: Doubled-referenced BLI responses and calculated KD values with steady state graph
curve fit R2 following 10-point dilution of 10 virtual screen compounds. Both pH 6.0 and pH 7.5
results are shown, and the 2 hits considered most promising are highlighted in blue.
Of these 10 compounds screen at 2 varying pH values, the majority showed either low
response values (< 0.05 nm), millimolar or higher KD values, or poor steady state curve
fits. Based on this, no compounds from pH 6.0 were considered for further analysis.
Compounds D3 and E2 at pH 7.5 showed acceptable response at 2500 μM and showed
high micromolar D values, but were excluded from further evaluation based on their
association behaviors. The 2 compounds considered to have good binding behavior at
pH 7.5 were A1 (KD=320 ± 26 μM) and B1 (KD=410 ± 61 μM), the structures and
binding behaviors of which are shown in Figure 4.4.
Whether or not these compounds competed with the binding of pantothenate was
further investigated. In a separate BLI test, compound A1 was maintained at a constant
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(a) Compound A1 (b) A1 response curves (c) A1 steady state
(d) Compound B1 (e) B1 response curves (f) B1 steady state
(g) Pantothenate (h) Pantothenate response curves (i) Pantothenate steady state
Fig. 4.4: Structures and hit validation of the most promising compounds tested from the virtual
screen (a-f) and the pantothenate control included in the same test (g-i). KD and R2 of these
compounds are shown in the steady state graphs (c, f, i)
concentration of 1250 μM as pantothenate was serially diluted 2-fold from 50 μM to
0.19 μM. Triplicate measurements of the KD value of pantothenate in the presence
of constant A1 were performed, including duplicate measurements in the absence of
A1. Biotinylated 6HisAviPaPanK was loaded to a response of 7 nm at pH 7, and
the compound responses were measured with 60 s baseline, 60 s association, and 60 s
dissociation steps. The mean KD value of pantothenate in the absence of A1 (3.1 ± 0.18
μM, n=3) was not increased in the presence of A1, but found to decrease (1.6±0.29 μM,
n=2). The test was not repeated on compound B1 due to lack of available compound.
An alternate test dependent only on response values was performed with exposures
of sensors with biotinylated 6HisAviPaPanK and biocytin sensors to combinations of
A1, B1, and pantothenate. The goal was to determine whether the binding of each
compound was additive, partially additive, or inhibitory. Without dissociation in
between certain association steps, the sensors showed the differing behaviors of A1 and
B1 (Figure 4.5). The main takeaway from this graph is that after binding of a single
virtual screen hit (1.), the following association step (2.) with pantothenate added
varying degrees of panothenate response (3.) to the hit response (1.). in the case of
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compound A1 the responses appeared completely additive, with the full responses
of both pantothenate alone and A1 alone present when they were combined. In the
case of compound B1 the responses were only partially additive, and thus B1 was
tentatively considered to have at least some specifity for the pantothenate binding
site. A1 was removed from further consideration, while structural determination of the
binding mode via X-ray crystallography was later attempted for compound B1.
Fig. 4.5: BLI pantothenate inhibition testing of compounds A1 and B1, with association steps
labelled. 1) 312.5 μM of a single hit compound. 2) 312.5 μM hit compound + 25 μM pantothenate.
3) μM pantothenate. 4) 25 μM pantothenate + 312.5 μM of a single hit compound. 5) 312.5 μof a
single hit compound. 6) 312.5 μof both A1 and B1. 7) 25 μM pantothenate + 312.5 μM of a single hit
compound. 8) 312.5 μof both A1 and B1.
4.2.4 Fragment screen of EU-OS library
In order to increase the chances of finding potential PaPanK inhibitors beyond reliance
on virtual screening compounds, two separate fragment screening libraries were obtained.
Each compound would be assessed by BLI to determine which compounds appeared to
bind to PaPanK, while later refinement based on binding responses of the protein and
biocytin reference sensors would be used to narrow the results prior to a secondary hit-
validation experiment. The first library utilized was a 1047 sample subset of compounds
curated by EU-OPENSCREEN and designed for efficient fragment screening. Prior to
screening of these compounds biotinylated 6HisAviPaPanK (25 μg/mL) was bound
to SSA sensors alongside biocytin (10 μg/mL) controls for detection of nonspecific
binding as described in Method 3.10. Biotinylated 6HisAviPaPanK response upon
loading to sensors was consistent across all sensors to a level of 6 nm and the fragment
34 Results
screening proceeded. Each of the EU-OS compounds was screened at single 500 μM
concentrations for the detection of binding responses, with 30 s baseline, 30 s association,
and 40 s dissociation steps.
The biocytin sensor responses and PaPanK sensor responses were filtered to identify
hits using a workflow (Method 3.10.2). Initial filtering by excluding compounds with
responses > 0.1 nm or < -0.1 nm for biocytin sensors excluded 162 compounds. Next,
the mean biocytin response ± 1STD was calculated for the remaining compounds
(0.0158±0.0308) and a further 241 compounds with responses above this upper limit
and below this lower limit were excluded. In the final step the mean PaPanK response
minus biocytin response, + 1 STD was calculated (0.0096 + 0.0256) and filtered out
all compounds with responses < 0.027 nm. This step filtered out 565 compounds.
(a) Fast: EU-OS compound 3-1 F3 (b) Fast: EU-OS compound 5-1 C2
(c) Acceptable: EU-OS compound 5-1 D8 (d) Slow: EU-OS compound 5-1 G2
Fig. 4.6: Raw BLI data for PaPanK sensors from the 500 μM concentration screening of the EU-OS
library, with examples of association/dissociation curves visually evaluated after hit processing. Near-
instant binding to the PaPanK sensors was desired. The vertical red dotted lines separate baseline,
association, and dissociation steps. (a) and (b) show compounds which were visually determined to
have fast association and dissociation rates. The binding of (c) and 19 other compounds with similar
behaviors were deemed acceptably fast. The binding of (d) and 41 other compounds with similar
behaviors were deemed slow and excluded.
After all hit processing, 79 compounds (7.55% of evaluated compounds) were identified
as candidates for secondary screening. The binding profiles of these 79 compounds
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were evaluated visually in order to exclude compounds which associated or dissociated
in slow, roughly linear manners (Figure 4.6 d). 42 compounds were excluded based on
this criteria. Of the remaining compounds, 17 appeared to have unambiguously fast
on/off binding curves (Figure 4.6 a, b), while a further 20 appeared to bind more slowly
but not poorly enough to be excluded entirely (Figure 4.6 c). In total, 37 compounds
were designated for further hit validation.
EU-OS hit validation
The 37 EU-OS compounds filtered both by KNIME and by visual evaluation were
subject to further testing and KD determination using BLI and 5 serial 2-fold dilutions
from 500 μM to 31.3 μM. Pantothenate positive controls were serially diluted in the same
manner but from 25 μM to 1.56 μM and were present during the hit validation of each
compound. DMSO from the hit-picking plate from which compounds were manually
transferred was used to prepare the buffer-only reference wells and pantothenate positive
controls. 30 s baseline, 30 s association, and 40 s dissociation steps were used for all
compounds except for EUOS-hits 33-37, where the dissociation step was accidentally
omitted. EUOS-hit 7 was not tested due to accidental omission.
The resulting response values and calculated fitted curves did not reveal any clear hits
(Table 4.3). The pantothenate positive controls used on each plate appeared similar to
those shown previously (Figure 4.3c). 27/36 tested EU-OS compounds showed response
values < 0.027 nm, the KNIME cutoff established in Section 4.2.4. KD values for
compounds above this response threshold tended to be in the high millimolar or molar
range, or fit only moderately, weakly, or not at all. EUOS-hit 2 appeared acceptable,
but given its low maximum response it was not selected for further evaluation.
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EUOS Hit ID Max concentration (uM) Max Response (nm) KD R2
1 500 -0.0128 <1.0E-12 0
2 500 0.0289 7.20E-04 0.9778
3 500 0.0192 1.50E-04 0.7394
4 500 0.0287 1.80E-04 0.9239
5 500 0.0009 6.20E-06 0.004
6 500 0.0097 7.90E+10 0.9952
8 500 0.014 2.10E-03 0.9586
9 500 0.0225 <1.0E-12 0
10 500 0.0152 1.50E-02 0.96
11 500 0.0236 2.70E-04 0.9483
12 500 0.0003 <1.0E-12 0
13 500 0.0119 8.70E-05 0.7975
14 500 -0.0042 <1.0E-12 0
15 500 0.0151 7.50E-05 0.8867
16 500 0.034 <1.0E-12 0
17 500 0.0244 8.90E-05 0.9121
18 500 -0.0023 <1.0E-12 0
19 500 0.0091 7.70E+10 0.908
20 500 0.0017 <1.0E-12 0
21 500 0.0541 4.40E+11 0.8995
22 500 0.1368 <1.0E-12 0
23 500 0.0148 <1.0E-12 0
24 500 0.0601 9.30E+09 0.9941
25 500 0.0082 <1.0E-12 0
26 500 0.0518 1.30E-04 0.4456
27 500 0.2292 2.60E+11 0.9328
28 500 0.0275 2.70E-04 0.7549
29 500 -0.0112 <1.0E-12 0
30 500 0.0262 5.30E-04 0.9441
31 500 0.0024 <1.0E-12 0
32 500 0.0196 3.30E+11 0.8785
33 500 0.0034 4.30E-05 0.6859
34 500 0.0342 1.60E-03 0.9399
35 500 -0.3363 - -
36 500 0.0245 4.50E-04 0.9864
37 500 0.014 5.60E-04 0.8804
Table 4.3: Results from hit validation of 36 EU-OS compounds. KD values and R2 for BLI response
fits to the steady state graph used for KD determination are shown.
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4.2.5 Fragment screen of carboxylic acid library
A diverse library of 305 carboxylic acids was ordered given the importance of this
functional group in the interaction of pantothenate with several PaPanK active site
residues as described in Introduction 1.6. Three of the 305 compounds posed solubility
issues and thus the library which arrived contained 302 DMSO-solubulized compounds
for testing. Prior to screening of these compounds biotinylated 6HisAviPaPanK (25
μg/mL) was bound to SSA sensors alongside biocytin (10 μg/mL) controls for detection
of nonspecific binding described in Method 3.10. Biotinylated 6HisAviPaPanK response
upon loading to sensors was consistent across all sensors to a level of 6 nm and the
fragment screening proceeded. The 302 carboxylic acids were screened at single 500
μM concentrations for the detection of binding responses, with 30 s baseline, 30 s
association, and 40 s dissociation steps.
The responses for the sensors were processed through KNIME in the same way as
described for the EU-OS library. The mean biocytin response ± 1 STD was calculated
(-0.004±.018 nm) and compounds above this upper limit and below this lower limit
were excluded. Calculation of the mean PaPanK response - biocytin response, + 1STD
(0.012+0.039) filtered out all compounds with responses < 0.051 nm.
After all hit processing, 9 compounds (2.98% of evaluated compounds) were identified
as candidates for secondary screening. The binding profiles of these 9 compounds were
evaluated visually in order to exclude compounds which associated or dissociated in
slow, linear rather than logarithmic manners or showed otherwise irregular behavior. 3
of the 9 compounds were excluded based on this criteria. Likewise, compounds which
were narrowly filtered out by the KNIME workflow were visually evaluated and 4
such compounds were manually included. In total, 10 compounds were designated for
further hit validation.
Hit validation of carboxylic acids
As was performed for the EU-OS hits, the KD was calculated for the carboxylic acid
hits in order to identify compounds with the highest PaPanK affinity. DMSO from
the hit-picking plate from which compounds were manually transferred was used to
prepare the buffer-only reference wells. A hit validation experiment using 5 2-fold
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serial dilutions of the compounds selected from Section 4.2.5 was performed, with
concentrations ranging from 31.3 μM up to 500 μM.
Response was measured, steady state analysis was carried out, and structures of the
acid compounds were visualized (Table 4.4). The pantothenate control bound well to
the sensor, with a calculated KD of 1.7 μM, similar to the previously determined value
(Figure 4.3c). Hits 9 and 10 of the carboxylic acid library (Table 4.4) showed responses
lower than the 0.051 nm threshold utilized previously (Section 4.2.5) and individual
responses did not fit well to the steady state curve used to calculate KD. Acid hits 2
and 3 (Table 4.4) were excluded as they did not appear to bind quickly to or dissociate
well from the sensors and provided millimolar KD values. Carboxylic acid hits 1, 4, 5,
6, 7, and 8 all produced sub-millimolar dissociation constants, with hit 7 (Table 4.4)
showing the greatest affinity with a KD value of 110 μM. These binding responses and
association/dissociation behaviors were also deemed acceptable.
Table 4.4: Resulting binding curves and steady state responses used for KD determination of
carboxylic acid hit validation compounds. The RDkit rendered structures are included. ’Hit’ refers to
the carboxylic acid compounds selected for hit-validation following Results 4.2.5. Column ’Binding’
shows the double-referenced responses for each serially diluted compound. Column Steady State’
shows the fitted curves used to calculate KD. Pant’ under the ’Hit’ column refers to pantothenate,
used as a positive control.
Hit Structure Binding Steady State
Pant
1
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A BLI binding assay was successfully established using biotinylated 6HisAviPaPanK.
BLI sensors could be reliably loaded with biotinylated 6HisAviPaPanK and used to
assess the binding of known ligands as well as a large number of compounds from a
virtual screen and two fragment libraries. Based on analysis of the results, several hits
were identified.
4.3.1 Expression and purification of 6HisAviPaPanK
Biotinylation of PaPanK was necessary in order to load it to streptavidin-coated
biosensors for BLI measurements. Site-specific biotinylation was desired to ensure
that sensors could be loaded uniformly. Therefore, 6HisAviPaPanK, which possesses a
6His-tag for purification by IMAC as well as an AviTag for site specific biotinylation
was expressed [61].
Following initial purification of lysate utilizing a His-trap IMAC column, multiple
peaks were observed (A.1). The low levels of imidazole (20 mM) present early in the
purification seemed sufficient to prevent nonspecific binding to the column, and a vast
majority of the cell lysate flowed through (peak A). As the concentration of imidazole
increased (from 20 mM during sample application and washing, followed by gradient
elution eventually reaching 500 mM imidazole), sample which had bound the column
appeared to have been displaced for collection. High, > 80 mM concentrations of
imidazole have been shown to displace 6His-tagged proteins by chelation of Ni2+, and
thus 6HisAviPaPanK was suspected to be present in Peak B [62]. Later size-exclusion
chromatography was used to further purify the protein and Peak C (Figure A.2) was
suspected to contain the 6HisAviPaPanK. Two smaller peaks, A and B, may have
consisted of either denatured 6HisAviPaPanK, 6HisAviPaPanK which hydrolyzed at
some point following His-trap purification, or non-desired proteins or compounds which
bound to the His-trap column more strongly than expected. The SDS-PAGE performed
on this suspected 6HisAviPaPanK revealed a mostly pure band between the 25 and 37
kDa ladder bands (Figure 4.1), consistent with the 31.4 kDa mass of the recombinant
protein. A fainter band was observed closer to the 25 kDa ladder bands and may
indicate partial hydrolysis of the protein, resulting in a fraction which traversed the
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polyacrylamide matrix slightly faster. It could also be due to a protein having co-eluted
during IMAC and being too similar in size to be separated by SEC. Still, this protein
was deemed adequately purified given that enzymatic biotinylation would introduce
additional purification steps. Assuming efficient enzymatic biotinylation, the overall
yield of 14.93 mg was greatly in excess of that required for many BLI experiments.
The biotinylation of 6HisAviPaPanK by BirA would later be confirmed by loading of
the protein to SSA sensors.
4.3.2 BLI with PaPanK
4.3.3 Protein loading optimization
Adsorption of biotinylayed 6HisAviPaPanK onto SSA sensors was necessary prior to
the assessment of small molecule binding. Given that BLI is designed to measure
interference based on the optical density of bound molecules, a high degree of pro-
tein binding was desired in order to measure the likely low contribution to optical
density provided by low molecular weight screening compounds. The biotinylated
6HisAviPaPanK loading took place over 5 minutes (Figure 4.2) to accommodate the
diffusion limited Kon of biotin, reaching between 5 nm response at 12.5 μg/mL and 11
nm at 250 μg/mL. The dissociation step following protein loading showed only a slight
drop in response after protein loading, indicating a minimal change in optical density
and confirming that protein loading and enzymatic biotinylation of 6HisAviPaPanK
were successful. The extremely low Koff of the biotin-streptavidin interaction [63]
means that detachment from the sensor should be slow, though reference sensors are
still needed to account for drift.
Concentrations of both 25 μg/mL (7 nm response) and 100 μg/mL (9.5 nm response)
were considered to have adequate amounts of protein adsorption based on the work
of Martin et al. (2011) where a protein loading response of 10 nm was reached after
approximately 10 minutes for use in fragment screening [48]. While 250 μg/mL did
reach the highest levels of binding response observed, it required 10-fold more protein
for a 1.6-fold increase in binding relative to loading at 25 μg/mL. Thus, 25-100 μg/mL
biotinylated 6HisAviPaPanK was used for fragment screening and ligand analysis.
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Establishment of ATP and pantothenate binding
In order to use BLI for screening of fragment libraries and the virtual screening
compounds, confirmation of the binding of confirmed PaPanK ligands was required.
The binding of pantothenate was consistent with previous data, with a KD of 2.5 ±
0.15 μM with two replicates (Figure 4.3d). Clear saturation was observed, with only
minimal increases in response measured with successive doubling of concentration
above 25 μM (Figure 4.3, c). Although this was a low degree of confidence given only 2
measurements, similar values were observed with the use of pantothenate as a control
throughout the fragment screening process. While 0.01% (v/v) Triton X-100 was
included in follow-up experiments in order to limit aggregation, ATP measurements
were not repeated with the inclusion of ATP and thus aggregation contributing to the
high response cannot be ruled out. ATP is considered to be freely soluble in water [64],
so aggregation may not be at play if the 5% (v/v) DMSO is compatible with ATP.
Based on these results, pantothenate was considered validated for use as a positive
control during fragment screening. ATP likely requires further validation despite its
similarity to historical KM values, as it was subject to limited testing.
Fragment screen of virtual hits
Fragment screening of virtual hits attained by Lee (2020) revealed 10 compounds out
of 17 which showed double-referenced BLI responses which exceeded 0.05 nm at at one
or both of pH 6.0 and pH 7.5 (Table 4.1). This initial hit rate following preliminary
screening is much higher than would be expected from a library-based fragment screen,
but is not completely out of the realm of possibility as structure-based virtual screens
have been performed with high rates of inhibitor identification [65]. KD determination
of these 10 initial hits was carried out at both pH 6.0 and pH 7.5 and narrowed the
field considerably, with only 2 compounds (Table 4.2), A1 and B1, being considered
for further evaluation based on their responses and equilibrium dissociation constants
at pH 7.5. Both showed 3-400 μM KD values and individual concentration points
fit well to the steady state plots (Figure 4.4). Maximum response values were lower
when comparing the hit validation results (4.2) with the 2-point fragment screening
results (4.1), which could be because a 4-fold lower concentration of μg/mL biotinylated
6HisAviPaPanK was used in the hit validation experiment. The pantothenate positive
44 Results
control responses were also lower given the reduced amount of protein loading, but
still arrived at KD values between 1.6 and 3.1 μM with R2 > 0.97 across all tests (not
shown).
The competitive inhibition experiment where pantothenate was used to outcompete any
pre-bound compound A1 or B1 present in the PaPanK binding pocket gave somewhat
ambiguous results (Figure 4.5). The binding responses of both A1 and pantothenate
appeared to be fully additive, which indicated that they occupied entirely different
binding pockets and likely ruled out compound A1 as a potential inhibitor. If they
bound exclusively to the same pocket, the response was expected to be reduced when
compared to at least one of the pantothenate-only or A1 only control association
steps, yet this was not observed. KD determination of pantothenate in the presence
of constant 1250 μM compound A1 seemed to confirm this, as the calculated KD was
lower in the presence of compound A1 than with pantothenate alone. In the case
of compound B1 the response of pantothenate and B1 were only partially additive,
perhaps indicating that B1 binds both to the binding pocket as well as elsewhere to
the PaPanK. More B1 than was available would have been necessary to determine
the KD of pantothenate in the presence of B1, though such an experiment would have
been highly informative. While not ideal as B1 appeared to compete at least partially
with pantothenate, B1 was prioritized for crystallization experiments to determine its
binding mode via x-ray crystallography.
Fragment screen of EU-OS library
A subset of the EU-OS library was utilized in order to effectively test a much larger
library, as the 1047 compounds were curated by the manufacturer to be representative
of their > 100000 compound fragment library. A more focused screen could then be
conducted based on compounds in their repository with structural similarities to any
confirmed hits. Despite single-concentration screening and hit-validation testing of
these compounds, ultimately no compounds appeared promising enough for further
analysis (Table 4.3). The presence of a carboxylate group as in pantothenate may be
necessary for specific binding to the active site of PaPanK. The EU-OS contained only
2 carboxylic acids in total, and this may suggest that compounds lacking a carboxylate
group (as is present in pantothenate) are unlikely to bind, and conversely that a
carboxylate group may be necessary for strong binding to the active site.
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Fragment screen of a carboxylic acid library
Based on the importance of the carboxylate group of pantothenate in its interaction with
the active site of PaPanK, and its high incidence rate in the virtual screen compounds,
a library consisting of carboxylic acids was tested via BLI. During KNIME refinement
based on biocytin control responses and PaPanK responses, the mean biocytin response
±1 STD (.004 ± .018 nm) was considerably lower than that from the EU-OS library. It
could be true that the increased solubility attributed to the carboxylate group reduces
aggregation during BLI, resulting in fewer nonspecific binding events. The carboxylic
acid compounds were specifically filtered beforehand to include only compounds with
calculated solubility (cLogS) ≤ -1.5. Indeed, only 4/302 carboxylic acids tests showed
biocytin responses above 0.1 nm or below -0.1 nm, the extreme acceptable bounds
used for initial refinement. Owing to this apparent lack of nonspecific interactions, few
compounds showed PaPanK responses greater than the mean + 1STD (0.012 + 0.039
nm), and only 9 compounds (2.98 %) were identified through the KNIME workflow as
candidates for hit validation. This lack of overall non-specificity could mean that only
the most energetically favorable of interactions between the carboxylate and active site
residues is possible, limiting the number of hits but with an increased likelihood of hits
having real active site affinity. After visual evaluation, 10 compounds were ultimately
hit-validated through serial dilutions and determination of KD (Table 4.4).
Following serial dilutions of these compounds for KD value determination (Table
4.4), 6 appeared to show readily saturable binding with sub millimolar KD values (1, 4,
5, 6, 7, and 8), which includes 2 of the 4 compounds which were included manually
despite elimination from the KNIME workflow (Table 4.4 hits 7 and 8), owing to
the appearance of their association/dissociation curves and only marginally excessive
biocytin responses. These 2 compounds showed the highest response values and lowest,
< 200 μM KD values of the 6 compounds deemed acceptable, which could indicate that
the KNIME workflow was too stringent. The KNIME workflow could be tweaked to
account for more factors than response values alone, as the BLI also measures Kon
and Koff rates. Further analysis of these compounds in order to determine binding





5.1 Expression and Purification of 6HisTEVPaPanK
While BLI provides information about binding of compounds and can be used to narrow
down a search for fragments with affinity for PaPanK, it does not confirm active site
specificity and does not provide binding mode information. Therefore the diffraction
of PaPanK crystals bound to fragments was desired. In order to produce PaPanK
crystals, a protein with a small, or removable purification tag was desired so as to
not interfere with crystal formation. 6HisTEVPaPanK was used, containing only a
6-peptide histidine purification tag and a TEV protease cleavage site in addition to
the full PaPanK primary sequence.
. In order to attempt crystallization of non-cleaved 6HisTEVPaPanK, expression and
purification were performed in the same manner as for 6HisAviPaPanK. Following
purification by both a His-Trap and SEC, 16 mg of suspected 6HisTEVPaPanK was
recovered based on the ÄKTA’s built-in UV meter and an A280 0.1% of 0.677 for a
total yield of 4 mg purified protein per liter of E. coli. 3 adjacent elution fractions
were run on a gel prior to pooling, and their sizes were consistent with the 29.4 kDa of
6HisTEVPaPanK (Figure 5.1). Overloading appeared evident in lane 2 as the loaded
amounts were not normalized.
In order to obtain PaPanK without an affinity tag for use in additional crystallization
trials 6HisTEVPaPanK was expressed again, but was not subject to purification by
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Fig. 5.1: SDS-PAGE for size and purity determination of 6HisTEVPaPanK following both His-Trap
purification and SEC. Lanes 1-3 contain eluted SEC fractions suspected to contain 6HisTEVPaPanK.
Lane 4 is empty. Lane L contains Precision Plus Protein™ Dual Xtra standard.
SEC. Following His-Trap purification, 39.45 mg of suspected 6HisTEVPaPanK was
collected based on the built-in UV meter and an A280 0.1% of 0.677. Approximately
half of this protein was later subject to tag-cleavage by TEV protease, and the protein
prior to cleavage is shown in lane 4 in the following section (Figure 5.2)
5.1.1 TEV protease cleavage of 6HisTEVPaPanK
As an alternative to crystallizing PaPanK with a 6His-tag, TEV protease was used to
cleave the added residues to allow for structural determination of the wild-type protein.
The observation of large tag-cleaved PaPanK crystals in unpublished data provided
further justification for tag cleavage. 6HisTEVPaPanK was treated with TEV protease
at a protease : PaPanK protein mass ratio of 1 : 10 according to Method 3.7 at a
temperature of 8C overnight. SDS-PAGE of the cleaved protein was performed prior
to purification, and a band consistent with cleavage of the short 6His-tag was observed
in Lane 3, when compared to the non-cleaved control in Lane 4 (5.2).
Fig. 5.2: SDS-PAGE for determination of 6His-tag cleavage stained with PageBlue. L) Protein ladder.
1) empty. 2) TEV protease normalized to lane 3. 3) PaPanK following TEV protease treatment. 4)
6HisTEVPaPanK prior to cleavage
Individually cleaved sample tubes were subject to reverse His-trap purification as
previously described (Method 3.7), and a large, isolated peak (Figure A.3 peak A) was
observed during the washing phase with loading buffer (20 mM Tris HCl pH 7.9, 500
mM NaCl, 20mM Imidazole, 10% v/v glycerol). Based on the built in UV meter using
the A280 0.1% of 0.677 (the value of which does not change upon cleavage), 12.47 mg
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was recovered of an initial 17 mg input leading to a combined cleavage and recovery
rate of 73%. SDS-PAGE was not performed on this protein following TEV cleavage
and reverse His-Trap purification, but a small scale test (not shown) showed only an
isolated, pure band which appeared to be smaller than the non-cleaved control.
5.2 Crystallization of PaPanK
Crystallization of PaPanK was desired in order to perform x-ray diffraction of PaPanK
bound to ligands, including hits from BLI screening. A variety of commercial screening
plates were tested on non-cleaved 6HisTEVPaPanK as described in Method 3.11,
however these yielded only small needles that could pose difficulties for diffraction
(Figure 5.3). Failed attempts were also made to crystallize 6HisTEVPaPanK in hanging
drops per the method outlined in Hong et al. (2006), though the literature attempt
differed in that it included Se-Met PaPanK with no affinity tag [35]. Thus, the
crystallization of TEV-cleaved PaPanK was prioritized. A previous master’s student
expressed, purified, and cleaved 6HisTevPaPanK with TEV protease and observed
the formation of needle-like crystals which did not diffract [49]. In a review of their
unpublished data, it was discovered that they had produced larger, ~50 μM wide singly
occurring crystals using well E12 of the JCSG-plus crystallization buffer screen (100
mM Imidazole pH 8.0, 10% (w/v) PEG8000) and with PaPanK buffer exchanged to 50
mM Tris-HCl pH 7.5. Therefore, it was attempted to reproduce crystals under these
conditions.
Fig. 5.3: A representative example of the numerous needle-like crystals which often formed when
attempting to crystallize 6HisTEVPaPanK without cleavage of the 6His-tag. This particular crystal
utilized 100 mM Bis-Tris Propane pH 6.5, 200 mM NaI, 10% (w/v) PEG3350, 10% (w/v) ethylene
glycol, and 6HisTEVPaPanK at 22 mg/mL. A drop ratio of 150 nL protein:150 nL precipitant was
used, and the crystal formed at 8 °C
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In this work, frozen aliquots of this PaPanK were thawed on ice and buffer exchanged
to 50 mM Tris-HCl pH 7.5 in order to remove glycerol. An optimization plate was
produced, with varying protein concentrations, PEG concentrations, and precipitant
pH values (Figure 5.4). Each of these 96 conditions varied also by protein : precipitant
volume ratios, as either 100:200 nL, 150:150 nL, or 200:100 nL on the crystallization
plate. Nucleation was almost immediate under many conditions, with visible crystals
forming within the several minutes between sitting-drop placement and initial imaging.
After 18 hours crystals at pH 7.5 were predominantly needles with many clustered
crystals (Figure 5.5a). The lowest protein concentrations also appeared to favor needle
formation under all conditions tested (full data not shown).
Fig. 5.4: Plate layout of tag-cleaved PaPanK crystallization optimization. Each condition was tested
at 3 different drop ratios as described, and crystal conditions selected for diffraction are highlighted
in green with the drop ratio number included: ’1’ = 150 nL protein:150 nL precipitant, ’2’ = 100
nL protein:200 nL precipitant, ’3’ = 200 nL protein:100 nL precipitant. ’Mg/mL P’ represents the
protein concentration of PaPanK placed into drops. The varying percentage values represent the %
(w/v) of PEG8000 in the precipitant.
The crystals which formed at pH 8.0 were generally the largest and least clustered.
When comparing drop ratios, ratios of 150 nL protein : 150 nL precipitant resulted in
similar crystals to those formed at a ratio of 200 : 100 (Figure 5.5b, c), however the
(a) pH 7.5 crystal (b) pH 8.0 crystal (c) pH 8.5 crystal
Fig. 5.5: Three His-tag cleaved PaPanK crystals imaged after 1 day 12 hours with 150 nL protein :
150 nL precipitant, 16.8 mg/mL protein, 100 mM imidazole, 8% (w/v) PEG8000 varying only by pH
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latter crystals appeared to degrade more rapidly. Thus, condition F5-1 (Figure 5.5 b)
was selected for use in future crystallography experiments.
5.2.1 Determination of suitable cryoprotectant
As described in Introduction 1.7, modern X-ray beamlines operate at temperatures
below 120 K to reduce radiation damage, which makes cryoprotection necessary
in order to avoid the formation of ice crystals. Although PEG8000 can act as a
cryoprotectant, the previously chosen crystallization condition contained too little
to be considered cryoprotected. Several cryoprotectants from the Cryosol MD1-90
(Molecular Dimensions) kit were added to PaPanK crystals as in Method 3.11.1. Only
cryomixes (CM)-1, 2, and 3 were tested on intact crystals since the other crystal drops
evaporated before the addition of cryomix. Images were taken of the crystals before
and 21 hours after the addition of cryomixes, and the cryomixes were tolerated to
varying degrees (Figure 5.6). Crystals appeared to have dissolved slightly under all
conditions, while dark aggregates formed in CM-1 and CM-3. Each of the 3 cryomixes
were selected for use as cryoprotectants in the proceeding trial in case one or more
proved to hinder diffraction.
(a) CM-1 test before addition. (b) CM-2 test before addition. (c) CM-3 test before addition.
(d) CM-1 after 21 hour expo-
sure.
(e) CM-2 after 21 hour expo-
sure.
(f) CM-3 after 21 hour expo-
sure.
Fig. 5.6: Effect of Cryomix 1-3 on PaPank crystals before treatment and after 21 hours of soaking
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5.2.2 Diffraction and structural confirmation of PaPanK and
various ligands
While condition F5-1 from the optimization plate (100 mM Imidazole pH 8.0, 8%
w/v PEG8000, 150 nL protein : 150 nL well buffer, input PaPanK concentration 16.8
mg/mL) appeared most visually appealing, a number of other crystals from this plate
also appeared suitable for attempting diffraction. After growing crystals, they were
fished using loops and cryoprotected prior to flash-freezing and shipping to various
beamline facilities. For the diffraction of apo-enzymes, crystals were cryoprotected by
directly adding 500 nL of the selected cryomix solution diluted using the crystal-specific
well buffer condition to the drop. Each of the 3 cryomix solutions which were tested
on PaPanK crystals (Figure 5.6) were included with large crystals which formed in the
optimization plate (Figure 5.4).
For several crystals, ligands at concentrations far exceeding experimental KD values
were included in the cryomix solutions and soaked by direct addition to the crystal
drops for approximately 15 minutes (Figure 5.1). When soaking, the concentrations
were 7.8 mM (A1), 7.8 mM (B1) and 6.5 mM (Pantothenate) within the crystal drops.
Flash-frozen protein crystals were beamed at the BioMAX MAX IV synchotron in
Lund, Sweden, and the resolutions at which crystals diffracted, along with ice-presence,
are shown in Table 5.1. The majority of crystals which did not form ice diffracted at
useful resolutions < 3.0 Å, with 4/12 (33.34%) of crystals from which data was collected
diffracting better than 2.0 Å. 6/7 crystals which utilized cryomix 1 for cryoprotection
developed ice, and the two crystals which did diffract did under these conditions so
at the lowest resolutions of 2.9 and 2.92 Å. Cryomix 1 was therefore excluded from
further use as a cryoprotectant.
The collected data were further processed according to Method 3.11.4 and diffraction
and refinement data are displayed in Table A.1. Only the structure of the PaPanK
dimer was visible for the crystals which were soaked with virtual screen ligands A1 or
B1, which indicated a lack of binding under these conditions. Complete structures
of the apoenzyme as well as PaPanK-Pantothenate were determined (Figure 5.7).
Pantothenate could be seen binding to both chains of the homodimer at the dimer
interface with the same binding mode as previously shown in PDB 2F9W (Figure 5.7a)
[35]. The carboxylate group of pantothenate formed hydrogen bonds with Tyr92 Gly99,
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Crystal location Ligand Resolution (Å)/Ice Cryomix
B5-1 Apo Ice 1
B9-1 Apo Ice 3
C5-1 Apo Ice 1
C5-1 Apo Ice 1
C6-1 Apo 1.9 2
C6-1 Apo 2.4 2
F5-1 Apo 2.92 1
F5-1 Apo Ice 1
F8-1 Apo 2.9 /Ice 1
F8-1 Apo Ice 1
F9-1 Apo 2.11 3
F9-1 Apo No crystal 3
E7-2 Apo 1.9 3
E7-2 Apo No crystal 3
D5-1 B1 2.23 3
D5-3 B1 2.27 3
D5-1 B1 Ice 3
E5-1 Pantothenate 1,95 3
E5-1 Pantothenate 1.82 3
E5-3 A1 2.8 3
G5-1 A1 2.03 3
G5-3 Pantothenate 2.11 3
Table 5.1: Data collection from crystals fished and optionally soaked with ligands from the optimiza-
tion plate. Samples were soaked with varying cryomix solutions, while samples in blue were soaked
with cryomix containing the highlighted ligand. B1 and A1 are hits from fragment screening of the
virtual screen compounds (Section 4.2.3)
.
and Arg102 of one chain and Thr 180 of the opposing chain (Figure 5.7b). Asp101
stabilized the opposite end of pantothenate, interacting with two separate hydroxyl
groups.
Various structural alignments were performed in order to gauge the level of similarity
between historical structures and those obtained in this work (Table 5.2). The main
chain residues of the apoenzyme and pantothenate-PaPanK were aligned with an rmsd
of 0.642 Å. Alignment of the PaPanK-pantothenate with the previously published
Se-Met PaPanK-Pantothenate (PDB 2F9w) gave an rmsd of 0.943 Å. The apoenzyme
PaPanK did not show the locations of residues between Arg154 and Tyr162 on chain
A, varying slightly from the apoenzyme Se-Met PaPanK (PDB 2F9T) which lacked
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(a) PaPanK active site interaction with pantothenate.
(b) Full ribbon view of PaPanK bound to pantothenate,
with two pantothenate units visible at the dimer interface.
Fig. 5.7: (above) PaPanK homodimer bound to pantothenate, zoomed in to pantothenate binding
site (a), and full view (b). PAU represents pantothenate, active site residues contributing hydrogen
bonds (dashed lines) are labelled and displayed as sticks. Chain A is colored cyan and chain B is
orange. Only PaPanK residues and pantothenate are displayed for clarity.
Reference structure Alignment structure rmsd (Å)









PaPanK-Pant Se-Met PaPanK-Pant(PDB 2F9W) 0.943
Apo PaPanK Apo Se-Met PaPanK(PDB 2F9T) 1.066
Table 5.2: rmsd (Å) values calculated in Chimera X using the Needleman-Wunsch sequence alignment
algorithm for the PaPanK apoenzyme, PaPanK-pantothenate, Chain A and Chain B comparisons from
within the same structures, and comparison with historical PDB entries which contained selenium-
methionine in lieu of methionine. ’Apo’ represents unbound apoenzymes while ’Pant’ represents
the ligand pantothenate. The best aligning chains were selected for comparison of the Se-Met and
wild-type PaPanK structures.
information for the residues between Arg154 and Asp164. This non-mapped region was
however present in the PaPanK-pantothenate and Se-Met PaPanK-pantothenate (PDB
2F9W) structures. Overall, there tended to be little variation between the aligned
structures.
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Structural determination of PaPanK-ATP and PaPanK-B1
The diffraction of PaPanK crystals showing the binding modes of previously unpublished
ligands was desired, as such information could be used to identify strongly binding
ligands in the future. Repeated attempts were made to diffract PaPanK soaked with
compound B1 from the virtual screen as well as a variety of other ligands. Soaking
with pantothenate and AMP-PNP, an inactive ATP analogue, did not indicate electron
density for AMP-PNP. A combination of ATP and pantothenate could not be soaked due
to their reactivity. After several unsuccessful soaking and diffraction trials, evidence of
compound B1 as well as ATP binding were seen in separate structures after performing
an alternative soaking protocol per Method 3.11.3, in which the KCl concentration was
increased and crystals were soaked in the absence of cryoprotectant. Data collections
took place with the DESY P11 synchotron in Hamburg, Germany. The data collection,
processing and refinement statistics for PaPanK-B1 and PaPanKATP are summarized
in Appendix A.1.
(a) Aligned molecular models of diffracted PaPanK
crystals obtained separately from virtual screen com-
pound B1 and pantothenate. Only protein residues
and H-bonds from the PaPanK-pantothenate struc-
ture are shown. PAU represents pantothenate while
LIG represents compound B1.
(b) Fo-Fc map of compound B1, with electron density
with B1 excluded from the model shown as a grid.
Fig. 5.8: Preliminary x-ray structures for determination of the binding mode of compound B1. (a)
Alignment of the previously shown PaPanK-Pantothenate structure with PaPanK-B1. (b) The Fo-Fc
omit map for compound B1 used to show electron density without molecular model bias.
Preliminary refinement of the diffraction data of PaPanK-B1 revealed binding of
compound B1 to the active site of PaPanK. Notably, the ligand was only visible at
the dimer interface consisting mostly of chain A protein residues. An alignment of the
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PaPanK-Pantothenate and PaPanK-B1 molecular models shows that both compounds
occupy similar spaces within the active site, particularly where the carboxylate moieties
are placed (Figure 5.8a). The preliminary model showed a relatively high ligand
B-factor of 81.04 Å2, indicating a degree of uncertainty in the placement of B1. An
Fo-Fc omit map was produced in order to determine whether electron density existed
to justify the placement of B1 within the molecular model (Figure 5.8b). The Fo-Fc
map mostly overlapped with the model of B1 within PaPanK, especially so at the
carboxylate moiety. Electron density at the opposite end was less well-defined. Based
on these observations, the approximate binding mode of virtual screening compound
B1 appeared to be confirmed.
Preliminary refinement of the diffraction data of PaPanK-ATP revealed binding of
ATP, which like B1 was visible at only one of two binding sites. Superimposition of the
PaPanK-ATP and PaPanK-Pantothenate chain A structures had an rmsd of 0.483 Å,
indicating a high degree of similarity between both structures. The predicted molecular
model also showed a relatively high B-factor of (Table A.1).
(a) Molecular model of PaPanK-ATP, with ATP and
Mg2+ within the ATP binding site. Only protein
residues contributing H-bonds are shown.
(b) Fo-Fc map of ATP, showing observed minus calcu-
lated electron density from the model prior to fitting
of ATP. The ’missing’ electron density is accounted
for by ATP.
Fig. 5.9: Preliminary x-ray structures for determination of the binding mode of compound B1. (a)
Alignment of the previously shown PaPanK-Pantothenate structure with PaPanK-B1. (b) The Fo-Fc
omit map for ATP used to show electron density with reduced molecular model bias. The molecule
has been rotated relative to figure (a) in order to more clearly display the electron density.
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5.3 Discussion: Protein crystallography
Well-diffracting PaPanK crystals were desirable as these could be used to assess the
binding modes of hits which resulted from BLI, as well as natural ligands which have
not yet been structurally determined when bound to PaPanK. 6HisTevPaPanK was
expressed and purified as it was hoped that its small tag would not heavily interfere
with crystallization, and could be removed by TEV protease if necessary. Ultimately
a number of largePaPanK crystals were produced, which were successfully used for
structural determination of the binding modes of various ligands at ~2.0 Å or better,
and at times served as an excellent complement to the BLI measurements.
5.3.1 Expression and purification of 6HisTEVPaPanK
In order to collect structural x-ray data from PaPanK and various ligands, the expression
of the protein was first required so that crystallization attempts could be made. The
protein was expressed without issue, with no optimization required as the protocol
had been previously established [49]. TEV protease cleavage of the 6His-tag was
also considered successful, with a relatively pure 27 kDa band (Figure 5.2, lane 3)
prior to reverse His-trap purification. While reverse His-trap revealed a singular peak
in the fraction expected to contain protein without a His-tag (Figure A.3, Peak A),
SDS-PAGE should have been performed for final size and purity confirmation prior to
crystallization attempts. The identity of this purified protein was later confirmed to
be tag-cleaved PaPanK by x-ray diffraction.
5.3.2 Crystallization of PaPanK
The formation of crystals of either PaPanK or 6HisTEVPaPanK was desired in order
to facilitate x-ray diffraction. Attempts to crystallize 6HisTEVPaPanK yielded at
best small needles, which would have posed difficulties both for fishing and diffraction.
It has previously been shown that N-terminal 6His-tags can be subject to variable
degrees of post-translational modifications in E. coli that can interfere with crystal
growth [66]. This could be a possibility, or it could be that by chance none of the
conditions tested were ideally suited for the formation of large crystals. When utilizing
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tag-cleaved PaPanK and variations based on well E12 of the JCSG-plus screen, large
crystals were readily producible. The absence of a 6His-tag was more desirable as
only the amino acid residues expressed by the CoaX gene would be present in any
successfully diffracted crystals. Cryoprotectant testing was conducted in order to
prevent ice crystals which might otherwise interfere with diffraction. The 21 hour test
revealed that the PaPanK crystals could tolerate each of the 3 applied cryoprotectants
(Figure 5.6). Dark aggregates appeared in CM-1 and CM-3 which both contained
DMSO, but given that 21 hours far exceeded the planned ligand/cryoprotectant soaking
time, all 3 were considered for later use.
5.3.3 Diffraction and structural confirmation of PaPanK and
various ligands
Diffraction of PaPanK and PaPanK-Pantothenate
In order to develop a pipeline for the structural determination of ligand-PaPanK
interactions, well-diffracting crystals were required. With the crystallization of PaPanK
established, attempts were made to diffract the protein both as an apoenzyme and
following soaking with cryomixes and ligands. A number of crystals indicated diffraction
at useful resolutions (Table 5.1) prior to further processing and refinement. Following
refinement of the molecular models generated from the electron density maps, molecular
models were produced which aligned well with the historical Se-Met PaPanK and
Se-Met PaPanK-pantothenate data, with fairly low rmsd (Å) (Figure 5.2). No major
structural differences were apparent upon visual comparison of the molecular models
with the historical Se-Met structures, and the disordered region beginning at Arg154
was was observed in both apoenzymes but not the pantothenate-bound enzymes.
Overall, the results from this trial confirmed that the methodology used in this work
could produce well-diffracting PaPanK crystals.
Diffraction of virtual screening compounds
The first attempt at diffraction of the 2 most promising virtual screening compounds (A1
and B1) was unsuccessful in identifying any electron density that would implicate their
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presence in the PaPanK structure, and only the apoenzymes were visible. Compound
A1 was subsequently ruled out based upon its apparent lack of competitive inhibition
with pantothenate and response-additivity during BLI (Figure 4.5). After several trials,
preliminary data suggested electron density for compound B1 in the active site of
PaPanK. As opposed to earlier soaking attempts, the successful attempt utilized a 56
mM KCl concentration during soaking and was soaked in the absence of cryoprotectant.
The preliminary PaPanK-B1 data indicated a high ligand B-factor of 81.04 Å2, relative
to the protein atoms B-factor of 58.63 Å2. This indicates that the certainty of the
location of individual B1 atoms within the active site is considerably less than that of
the surrounding protein atoms, and contrasts with the PaPanK-pantothenate structure
in which the ligand B-factor was lower than the protein atom B-factor. This is not
entirely unexpected given the weak binding indicated during BLI (B1 KD=410 μM),
as weakly binding compounds are not expected to completely bind to all predicted
binding sites and must compete for the binding sites with all other components used
during crystallization [67].
While a KD value of 410 μM isn’t especially weak when compared with ATP, it is
possible that the affinity is weaker than calculated given the partially additive BLI
response when combined with pantothenate as described in Discussion 4.3.3. Still,
the binding of B1 appears to be confirmed based on the omit map modelled without
B1, which clearly shows an area of electron density in the active site into which B1
can be readily accommodated (Figure 5.8b). Overlaying the PaPanK-model with
the preliminary PaPanK-B1 model also shows that the carboxylate groups of these
two ligands occupy very similar spaces within the active site. As evidenced by the
binding mode of pantothenate, the conservation of this interaction in B1 underlines the
importance of the carboxylate group in PaPanK active site affinity. Further, this result
appears to validate the methodology used for soaking with relatively weak ligands and
shows that the BLI screening methodology can identify small compounds with PaPanK
active site specificity. The fact that B1 was accurately predicted the virtual screen
conducted by Lee (2020) to bind to the active site of PaPanK coincides well with the
low rmsd (Å) between the previous Se-Met PaPanK models and the wild-type models
reported in this work (Table 5.2) [49]. Were the model highly inaccurate, simulated
binding modes might be expected to be inaccurate as well.
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Diffraction of PaPanK-ATP
Based on a preliminary refinement of diffraction data, ATP appeared to be present
at one of two PaPanK ATP binding sites (Figure 5.9a). The Fo-Fc omit map (Figure
5.9b) strongly indicates its presence, though still in need of further refinement. The
current lack of placement of water molecules in the refined model (Appendix A.1) likely
contributes to the relatively high Rfree of 0.25 when compared to the more refined
PaPanK and PaPanK-Pantothenate structures [68]. A high ligand B-factor relative to
the protein atoms (78.58 Å2 versus 58.63 Å2) indicates flexibility or uncertainty in the
ligand placement due to reduced/dispersed electron density. The millimolar KD and
KM values of ATP likely contribute to this high B-factor relative to the protein atoms,
possibly due to low occupancy or the high degree of movement allowed for by the lack of
strongly stabilizing interactions. Yang et al. (2008) also observed a considerably higher
B-factor for ADP than for protein residues in the structure of Thermotoga maritima
PanK-Pantothenate-ADP, another type III PanK with a similarly low affinity for ATP.
Further, the observed binding of ATP in the PaPanK-ATP structure is consistent with
the observation by Yang et al. (2008) that TmPanK bound AMP-PNP with equally
low affinity regardless of the presence or absence of pantothenate [33]. As previously
mentioned, the PaPanK-ATP model requires further refinement, but its ability to bind
PaPanK in the absence of pantothenate appears to be confirmed.
Chapter 6
Conclusion
Overall, considerable progress was made based on the original objectives of this thesis.
BLI utilizing enzymatically biotinylated 6HisAviPaPanK was successfully implemented
as a tool for screening large numbers of fragments with potential PaPanK specificity.
PaPanK crystals which consistently diffract at useful resolutions were produced, and
a method for soaking these PaPanK crystals with ligands as weakly binding as ATP
was developed. The molecular models produced from these diffracted crystals included
evidence for the binding mode of ATP in the absence of panothenate, as well as the
binding of a previous virtual screening compound, B1. The binding of this compound
served not just to validate the virtual and fragment screening processes, but also
provides a scaffold for chemical modifications which could be used to obtain a more
strongly binding ligand in the future, or to curate a library for similar compounds. The
6 hits from the carboxylic acid library have yet to be soaked with PaPanK crystals,
so there exists the potential for determining whether those compounds bind as well.
Future work on this topic could even adapt the methods developed here to conduct
high-throughput screening by X-ray crystallography.
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Fig. A.1: His-Trap HP purification of 6HisAviPaPanK. The first broad peak A represents the loading
of the column with lysate. The narrow Peak B represents protein which released from the column
after the imidazole concentration increased. This peak was saved for later processing. The flat Peak
C occurred at the highest concentrations of imidazole and was not processed further.
73
Fig. A.2: Further purification of 6HisAviPaPanK by SEC. Two small peaks A and B eluted just
prior to the large peak C. Peak C was expected to contain purified 6HisAviPaPanK and was saved for
further analysis.
74
Fig. A.3: Reverse His-trap purification following TEV protease cleavage of 6HisTEVPaPanK. ’%B’
on the right y axis denotes the percentage of elution buffer containing 500 mM imidazole is applied
to the column. Peak A denotes the sample which eluted during the binding buffer containing 20
mM wash phase and expected to contain tag-cleaved PaPanK. Peak B eluted during the isocratic
elution as elution buffer containing 500 mM imidazole was applied, and was expected to contain any
uncleaved 6HisTEVPaPanK and cleaved 6His tags. The flat ’peak’ C should contain high amounts of
imidazole, which absorbs UV light.
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